

19



Europäisches Patentamt
European Patent Office
Office européen des brevets

11 Publication number:

0 145 494
A2

12

EUROPEAN PATENT APPLICATION

21 Application number: 84308691.9

22 Date of filing: 13.12.84

51 Int. Cl.⁴: **C 07 D 327/02**, **C 07 D 411/06**,
C 07 D 411/12, **A 61 K 31/39**,
A 61 K 31/495

30 Priority: 14.12.83 **PC /JP83/004 36**
04.04.84 **PC /JP84/001 68**
01.11.84 **PC /JP84/005 26**

43 Date of publication of application: 19.06.85
Bulletin 85/25

84 Designated Contracting States: **AT BE CH DE FR GB IT**
LI LU NL SE


71 Applicant: **Takeda Chemical Industries, Ltd.**, 27,
Doshomachi 2-chome Higashi-ku, Osaka-shi
Osaka, 541 (JP)

72 Inventor: **Sugihara, Hirosada**, 5-604, 2-Minase 2-chome
Shimamoto-cho, Mishima-gun, Osaka 618 (JP)
Inventor: **Hirata, Minoru**, 26-13, Fushiodai 1-chome,
Ikeda-shi, Osaka 563 (JP)

74 Representative: **Laredo, Jack Joseph et al**, Elkington and
Fife High Holborn House 52/54 High Holborn, London,
WC1V 6SH (GB)

54 1,5-Benzoxathiepin derivatives, their production and use.

57 Novel 1,5-benzoxathiepin derivatives of the formula:



[wherein R_1 and R_2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy; R_3 and R_4 are independently hydrogen, optionally substituted lower alkyl or optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom; X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated; Y is $>C=O$ or $>CH-OR_5$ (wherein R_5 is hydrogen, acyl or optionally substituted carbamoyl); m is an integer of 0 to 2; n is an integer of 1 to 6] and salts thereof exhibit serotonin S_2 receptor blocking activity, calcium antagonism, actions to relieve cerebral vasospasm and to improve renal circulation

and diuretic and antithrombotic activities, and are of value as a prophylactic and therapeutic agent for ischemic cardiopathies, thrombosis, hypertension and cerebral circulatory disorders.


- 1 -

1,5-Benzoxathiepin Derivatives, Their Production and Use

The present invention relates to novel 1,5-benzoxathiepin derivatives which are of value as pharmaceuticals, and to a process for producing the same.

The present inventors, after intensive research to
 5 create a compound having specific serotonin S_2 receptor blocking activity, succeeded in producing novel 1,5-benzoxathiepin derivatives which exhibit not only excellent serotonin S_2 receptor blocking activity but also calcium antagonism, actions to relieve cerebral vasospasm and to
 10 improve renal circulation and diuretic and antithrombotic activities and are useful as a prophylactic and therapeutic agent for ischemic cardiopathies, such as angina pectoris and myocardial infarction, thrombosis, hypertension and cerebral circulatory disorders, such as cerebral vasospasm
 15 and transient ischemic attack, and have completed the present invention.

The present invention provides novel compounds of the formula:



[wherein R_1 and R_2 are independently hydrogen, halogen,
 25 hydroxy, lower alkyl or lower alkoxy; R_3 and R_4 are independently hydrogen, optionally substituted lower alkyl

or optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom; X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated; Y is $>C=O$ or $>CH-OR_5$ (wherein R_5 is hydrogen, acyl, or optionally substituted carbamoyl); m is an integer of 0 to 2; n is an integer of 1 to 6], salts thereof and a process for producing the same.

Referring to the above formula (I), the halogen represented by R_1 or R_2 includes, for example, fluorine, chlorine, bromine and iodine.

The lower alkyl group represented by R_1 or R_2 includes alkyl groups containing about 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, and the lower alkoxy group represented by R_1 or R_2 includes alkoxy groups containing about 1 to 4 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.

The case that one of R_1 and R_2 is hydrogen and the other is lower alkoxy is preferred and the case that said lower alkoxy group is attached at the 7th position of the benzoxathiepin moiety is more preferred.

The lower alkyl group represented by R_3 or R_4 includes alkyl groups containing about 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.

The said alkyl group may be substituted by, for example, C_{3-8} cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), halogen (e.g., fluorine, chlorine, bromine), hydroxy, lower(C_{1-4})-alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), lower(C_{1-5})-alkanoyloxy (e.g., acetoxy, propionyloxy, butyryloxy, pivaloyloxy), mono- or di-lower(C_{1-4})alkylamino (e.g., methylamino, dimethylamino, methylethylamino), C_{3-8} cycloalkylamino (e.g., cyclopentylamino, cyclohexylamino),

lower(C_{1-5})alkanoylamino (e.g., acetamide, propionamide), benzamide, lower(C_{1-4})alkylthio (e.g., methylthio, ethylthio, propylthio, butylthio), carbamoyl, N-lower(C_{1-4})alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl) or N,N-di-
5 lower(C_{1-4})alkylcarbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, methylethylcarbamoyl).

The cycloalkyl group represented by R_3 or R_4 includes cycloalkyl groups containing about 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
10 cycloheptyl and cyclooctyl, and the said cycloalkyl groups may be substituted for example by lower(C_{1-4})alkyl (e.g., methyl, ethyl, propyl, butyl, etc.), lower(C_{1-4})alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, etc.), lower(C_{1-5})alkanoylamino (e.g., acetamide, etc.) and hydroxy
15 groups.

The aralkyl group represented by R_3 or R_4 includes phenyl-lower(C_{1-4})alkyl groups, such as benzyl, phenethyl, 3-phenylpropyl, α -methylbenzyl, α -ethylbenzyl, α -methylphenethyl, β -methylphenethyl and β -ethylphenethyl, whereby
20 the phenyl group in the said phenyl-lower-alkyl groups may be substituted by 1 to 3 substituents, such as halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), lower- (C_{1-4})alkyl groups (e.g., methyl, ethyl, propyl, butyl, etc.), lower(C_{1-4})alkoxy groups (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, etc.), and methylenedioxy,
25 amino, nitro and hydroxy groups. Examples of such substituted-phenyl-lower alkyl groups include 2-(4-chlorophenyl)ethyl, 2-(4-hydroxyphenyl)ethyl, 2-(4-methoxyphenyl)-ethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(3,4,5-trimethoxyphenyl)ethyl, 2-(3,4-methylenedioxyphenyl)ethyl, 2-(p-tolyl)ethyl, 3,4-dimethoxybenzyl, 3,4-methylenedioxybenzyl, 3,4,5-trimethoxybenzyl, 4-ethylbenzyl, 4-chlorobenzyl, etc.
30

The ring which R_3 and R_4 forms with the adjacent nitrogen atom includes cyclic amino groups which may contain,
35 in addition to the said nitrogen atom, hetero atoms, such as nitrogen, oxygen and sulfur, and the cyclic amino groups

include 5- to 7-membered cyclic amino groups such as pyrrolidinyl, morpholinyl, piperidyl, piperadinyl and homopiperadinyl. The said cyclic amino groups may have substituents at any substitutive positions, and such substituents include, for example, lower(C₁₋₄)alkyl, (e.g., methyl, ethyl, propyl, butyl, etc.), aryl, aralkyl, acyl and hetero rings.

The aryl group as the substituent includes, for example, phenyl group, whereby the said phenyl group may be substituted by 1 to 3 substituents, such as halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), lower-(C₁₋₄)alkyl groups (e.g., methyl, ethyl, propyl, butyl, etc.), lower(C₁₋₄)alkoxy groups (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, etc.), and methylenedioxy, amino, nitro and hydroxy groups. The aralkyl as the substituent includes, for example, phenyl-lower(C₁₋₄)alkyl such as benzyl and phenethyl, diphenyl-lower(C₁₋₄)alkyl such as benzhydryl and triphenyl-lower(C₁₋₄)alkyl. The acyl as the substituent includes, for example, lower(C₁₋₄)-fatty acid residues such as lower(C₁₋₄)alkanoyl (e.g., acetyl, propionyl and butyryl) and aromatic organic acid residues such as benzoyl and phenyl-lower(C₁₋₄)alkanoyl and phenyl-lower(C₁₋₄)alkenoyl (e.g., cinnamoyl). The phenyl group in the said aralkyl groups and aromatic organic acid residues may be substituted by 1 to 3 substituents, such as halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), lower(C₁₋₄)alkyl groups (e.g., methyl, ethyl, propyl, butyl, etc.), lower(C₁₋₄)alkoxy groups (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, etc.), and methylenedioxy, amino, nitro and hydroxy groups. The hetero ring as the substituent includes 5- to 7-membered rings containing 1 to 3 nitrogen atoms, such as pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidyl, pyridazinyl, triazinyl and azepinyl.

As regards R₃ and R₄, is preferred the case that R₃ and R₄ together with the adjacent nitrogen atom form a

ring substituted by aryl, and the case that R_3 and R_4 together with the adjacent nitrogen atom form piperazinyl substituted by aryl is more preferred.

The lower alkyl group represented by X includes
5 alkyl groups containing about 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, whereby these groups may be substituted for example by oxo, hydroxy, acyloxy and aryl. The lower alkyl group substituted by oxo includes, for
10 example, lower(C_{1-4})alkanoyl, such as acetyl, propionyl and butyryl. The lower alkyl group substituted by hydroxy includes, for example, hydroxymethyl. The acyl group as the acyloxy group includes acyl groups derived from lower fatty acids, such as lower(C_{1-5})alkanoyl (e.g., acetyl,
15 propionyl and butyryl), and the lower alkyl group substituted by the said acyloxy group includes, for example, acetyloxymethyl, propionyloxymethyl and butyryloxymethyl. The lower alkyl group substituted by aryl includes, for example, lower(C_{1-4})alkyl substituted by phenyl group such
20 as benzyl, whereby the said phenyl group may be substituted by 1 to 3 substituents, such as halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), lower(C_{1-4})alkyl groups (e.g., methyl, ethyl, propyl, butyl, etc.), lower(C_{1-4})-alkoxy groups (e.g., methoxy, ethoxy, propoxy, isopropoxy,
25 butoxy, etc.), and methylenedioxy, amino, nitro and hydroxy groups.

The aryl group represented by X includes, for example, phenyl groups, whereby the said phenyl group may be substituted by 1 to 3 substituents, such as halogen (e.g.,
30 fluorine, chlorine, bromine, iodine, etc.), lower(C_{1-4})-alkyl groups (e.g., methyl, ethyl, propyl, butyl, etc.), lower(C_{1-4})alkoxy groups (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, etc.), and methylenedioxy, amino, nitro and hydroxy groups.

35 The esterified carboxyl group represented by X includes, for example, lower(C_{1-4})alkoxycarbonyl, such as

methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl and tert-butoxycarbonyl, and phenyl-lower-(C₁₋₄)alkoxycarbonyl, such as benzyloxycarbonyl.

5 The amidated carboxyl group represented by X includes, for example, carbamoyl groups, whereby the amino group in the said carbamoyl group may be substituted by 1 to 2 substituents, such as lower(C₁₋₄)alkyl, phenyl and phenyl-lower(C₁₋₄)alkyl. As regards X, an esterified carboxyl
10 group is preferred, and a lower alkoxycarbonyl group is more preferred.

 The acyl group represented by R₅ includes, for example, lower alkanoyl groups containing about 1 to 6 carbon atoms, such as acetyl, propionyl, butyryl, valeryl
15 and pivaloyl, and acyl groups derived from aromatic carboxylic acids, such as phenyl-lower(C₁₋₆)alkanoyl (e.g., benzoyl, phenylacetyl and phenylpropionyl); when the aromatic ring in the said aromatic carboxylic acid is a phenyl group, said phenyl group may be substituted by 1 to
20 3 substituents, such as halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), lower(C₁₋₄)alkyl groups (e.g., methyl, ethyl, propyl, butyl, etc.), lower(C₁₋₄)alkoxy groups (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, etc.), and methylenedioxy, amino, nitro and hydroxy group.

25 The optionally substituted carbamoyl group represented by R₅ includes, for example, carbamoyl, whereby the amino group in the said carbamoyl group may be substituted by lower alkyl (e.g., methyl, ethyl, propyl, butyl, etc.), phenyl, phenyl-lower(C₁₋₄)alkyl (e.g., benzyl, phenethyl, etc.), etc. The phenyl group in the said phenyl and
30 phenyl-lower-alkyl groups may be substituted by 1 to 3 substituents, such as halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), lower(C₁₋₄)alkyl groups (e.g., methyl, ethyl, propyl, butyl, etc.), lower(C₁₋₄)alkoxy
35 groups (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, etc.), and methylenedioxy, amino, nitro and hydroxy groups.


As regards Y, is preferred a hydroxymethine group.

The sulfur atom in the formula (I) forms, for example, sulfide, sulfoxide and sulfone, depending upon the value of m. The case that m is 0 is preferred.

5 The group $-(CH_2)_n-$ in the formula (I) forms, for example, methylene, ethylene, trimethylene, tetramethylene, pentamethylene and hexamethylene, depending upon the value of n. Among these groups, trimethylene is preferred.

10 Salts of the compounds (I) include pharmaceutically acceptable salts, such as salts with inorganic acids being exemplified by hydrochloride, hydrobromide, sulfate, nitrate, phosphate, etc., and salts with organic acids being exemplified by acetate, tartarate, citrate, fumarate, 15 maleate, toluenesulfonate, methanesulfonate, etc.

Preferred compounds (I) are those of the formula:



20

wherein R_6 is phenyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, R_2' is C_{1-4} alkoxy and X is C_{1-4} alkoxy carbonyl, and their pharmaceutically acceptable salts.

25

The compound (I) of the present invention can be produced, for example, by subjecting a compound of the formula:

30



35

[wherein the symbols are as defined hereinbefore] and a compound (III) of the formula:



[wherein n, R₃ and R₄ are as defined hereinbefore; W is
 5 halogen or a group represented by the formula R-SO₂-O-
 (wherein R is lower(C₁₋₄)alkyl, phenyl or p-tolyl)] to a
 condensation reaction, a condensation reaction and there-
 after a reduction reaction, or a condensation reaction and
 thereafter a reduction reaction, followed by an acylation
 10 or carbamoylation reaction.

The said condensation reaction is normally carried
 out in the presence of a base. The base includes, for
 example, inorganic bases, such as potassium carbonate,
 potassium hydrogencarbonate, sodium carbonate, sodium
 15 methoxide, sodium hydride and lithium diisopropylamide, and
 organic amines, such as triethylamine, pyridine and 1,8-
 diazabicyclo[5,4,0]-7-undecene. On this occasion, the
 reaction can also be allowed to proceed advantageously, for
 example, by using sodium iodide, potassium iodide, etc. as
 20 a catalyst. The above reaction can be normally conducted
 in an organic solvent (e.g., acetone, 2-butanone, aceto-
 nitrile, N,N-dimethylformamide, methylene chloride, benzene,
 toluene, tetrahydrofuran, dioxane, etc.) at a reaction
 temperature in the range of -20°C to +150°C, preferably
 25 +20°C to +120°C.

As a means of reducing the compound (I) wherein Y
 is >C=O as obtained by the condensation reaction, there may
 be mentioned reaction conditions of reduction with a metal
 hydride compound, such as lithium aluminum hydride, lithium
 30 borohydride, lithium cyanoborohydride, sodium borohydride,
 sodium cyanoborohydride and tri-tert-butoxylithium aluminum
 hydride; reduction with metallic sodium, metallic magnesium,
 etc. and alcohols; catalytic reduction using a metal,
 such as platinum, palladium and rhodium, or a mixture
 35 thereof with an arbitrary support as a catalyst; reduction
 with a metal, such as iron and zinc, and an acid, such as


hydrochloric acid and acetic acid; electrolytic reduction; reduction with a reducing enzyme; reduction with a boron hydride compound, such as diborane, or a complex compound of a boron hydride compound and an amine, such as borane-trimethylamine; and so forth. The above reaction is normally carried out in the presence of water or an organic solvent (e.g., methanol, ethanol, ethyl ether, dioxane, methylene chloride, chloroform, benzene, toluene, acetic acid, dimethylformamide, dimethylacetamide, etc.), and the reaction temperature varies with the reduction means employed, but generally is preferably in the range of -20°C to $+100^{\circ}\text{C}$.

The acylation or carbamoylation reaction subsequent to condensation and reduction can be carried out by use of ordinary means of an acylation or carbamoylation reaction of alcohol derivatives. The means of such acylation reaction can be realized, for example, by reacting with a reactive derivative (e.g., acid anhydride, acid halide, etc.) of an organic acid corresponding to R_5 in the presence of an organic amine, such as pyridine, triethylamine and N,N-dimethylaniline, or an inorganic base, such as sodium carbonate, potassium carbonate and sodium hydrogencarbonate. The above reaction is normally carried out in an organic solvent (e.g., methanol, ethanol, ethyl ether, dioxane, methylene chloride, toluene, dimethylformamide, pyridine, etc.), and the reaction temperature generally is preferably in the range of -20°C to $+100^{\circ}\text{C}$. The carbamoylation can be realized, for example, by reacting an alcohol derivative as obtained in the reduction reaction with an isocyanate derivative (e.g., methyl isocyanate, ethyl isocyanate, phenyl isocyanate, p-chlorophenyl isocyanate, etc.) corresponding to R_5 . The above reaction is normally carried out in an appropriate solvent (e.g., methanol, ethanol, acetonitrile, dioxane, tetrahydrofuran, methylene chloride, chloroform, toluene, N,N-dimethylformamide, etc.), and the reaction temperature generally

is preferably in the range of -20°C to $+150^{\circ}\text{C}$.

Also, the compound (I) of the present invention can be obtained, for example, by reacting a compound of the formula:

5



10 [wherein W' is halogen or a group represented by the formula $\text{R}'\text{-SO}_2\text{-O-}$ (wherein R' is lower (C_{1-4}) alkyl, phenyl or p-tolyl); other symbols are as defined hereinabove] with an amine derivative of the formula:

15




[wherein R_3 and R_4 are as defined hereinabove]. The reaction of the compound (IV) with the amine derivative (V) can be carried out in an appropriate solvent (e.g., methanol, ethanol, dioxane, acetonitrile, tetrahydrofuran, N,N-dimethylformamide, methylene chloride, dimethylsulfoxide and an arbitrary solvent mixture thereof). The reaction temperature is preferably in the range of 0°C to $+150^{\circ}\text{C}$, and for the purpose of increasing the reaction rate, organic base, such as triethylamine, pyridine and N,N-dimethylaniline, or an inorganic base, such as potassium carbonate, sodium carbonate and sodium hydrogencarbonate may be added as a catalyst.

After the said reaction, a compound of the formula (I) wherein Y is >C=O can be subjected to an acylation or carbamoylation reaction subsequent to the above-mentioned reduction method or reduction reaction to derive a compound of the formula (I) wherein Y is >CH-OR_5 .

The compound (I) of the present invention can also be produced, for example, by allowing a compound of the formula:

35




5 [wherein each of the symbols is as defined hereinbefore]
to undergo condensation with the compound (V) under reduc-
tive conditions.

10 The said reductive conditions include reaction
conditions of catalytic reduction using a metal, such as
platinum, palladium, Raney nickel and rhodium, or a mixture
thereof with an arbitrary support as a catalyst; reduction
with a metal hydride compound, such as lithium aluminum
hydride, lithium borohydride, lithium cyanoborohydride,
15 sodium borohydride and sodium cyanoborohydride; reduction
with metallic sodium, metallic magnesium, etc. and alcohols;
reduction with a metal, such as iron and zinc, and an
acid, such as hydrochloric acid and acetic acid; electrolytic
reduction; reduction with a reducing enzyme, and so forth.

20 The above reaction is normally carried out in the presence
of water or an organic solvent (e.g., methanol, ethanol,
ethyl ether, dioxane, methylene chloride, chloroform,
benzene, toluene, acetic acid, dimethylformamide, dimethyl-
sulfoxide, etc.), and the reaction temperature varies with
25 the means of reduction employed, and generally is preferably
in the range of -20°C to $+100^{\circ}\text{C}$. This reaction can be
conducted at atmospheric pressure to achieve the desired
object satisfactorily but may also be carried out under
pressure or under reduced pressure according to the
30 circumstances.

Furthermore, the compound (I) of the present invention
can be produced, for example, by subjecting a compound of
the formula:



5 [wherein each of the symbols is as defined hereinabove] to a reaction of reducing the amide group. The said reduction reaction can be carried out by use of means of reduction, such as reduction with lithium aluminum hydride, sodium dihydro-bis[2-methoxyethoxy]aluminate, sodium acetoxyboro-

10 hydride, aluminum hydride, diborane and alkyl borane. The above reaction is normally carried out in the presence of an organic solvent (e.g., ethyl ether, tetrahydrofuran, dioxane, toluene, benzene, etc.), and the reaction temperature varies with means of reduction employed, and

15 generally is preferably in the range of -20°C to $+120^{\circ}\text{C}$. In the case of a compound of the formula (VII) wherein X is, for example, esterified or amidated carboxyl and Y is $\text{C}=\text{O}$, in the said reduction reaction, these functional groups can be reduced simultaneously, and the desired

20 amide group alone can also be reduced by protecting the carbonyl group or by selecting a reducing agent, as the case may be.

A sulfoxide or sulfone compound of the formula (I) wherein m is 1 or 2 can also be produced by oxidizing the

25 corresponding sulfide compound. The said oxidation reaction is carried out, for example, by acting an organic peracid (e.g., m-chloroperbenzoic acid, peracetic acid, etc.) or inorganic acid (e.g., hydrogen peroxide, periodic acid, etc.). The above reaction is normally carried out

30 in the presence of an organic solvent (e.g., methanol, ethanol, dioxane, dichloromethane, etc.) within the temperature range of -20°C to $+100^{\circ}\text{C}$.

The object compound (I) of the present invention thus obtained can be isolated from the reaction mixture by

35 utilizing conventional separation and purification means, for example, means such as extraction, concentration,

neutralization, filtration, recrystallization, column chromatography and thin layer chromatography.

In the case of a compound of the formula (I) wherein Y is >CH-OR_5 , there exist at least two stereoisomers.

5 These individual isomers and a mixture thereof, naturally, both fall within the scope of the present invention, and such isomers can also be produced individually, if desired. For example, a single optical isomer of the compound (I) can be obtained by carrying out the above reaction using a
10 single isomer each of the starting compounds (IV) and (VI). When the product is a mixture of not less than two kinds of isomers, it can be separated into individual isomers by a usual separation technique, for example, separation means such as a method of forming salts with optically active
15 acids (e.g., camphorsulfonic acid, tartaric acid, dibenzoyl-tartaric acid, malic acid, etc.), a variety of chromatographic techniques and fractional recrystallization.

The compounds of the present invention, namely the 1,5-benzoxathiepin derivatives represented by the formula
20 (I), exhibit specific serotonin S_2 receptor blocking activity, calcium antagonism, actions to relieve cerebral vasospasm and to improve renal circulation, diuretic and antithrombotic activities in animals, in particular, mammals (e.g., humans, pigs, dogs, cats, rabbits, guinea
25 pigs, rats, etc.), and are useful, for example, as drugs for prevention and treatment of ischemic cardiopathies, such as angina pectoris and myocardial infarction, thrombosis, hypertension and cerebral circulatory disorders, such as cerebral vasospasm and transient ischemic attack.

30 The compounds of the present invention are of low toxicity, well absorbed even on oral administration and highly stable, and when they are used as the above-mentioned drugs, therefore, they can be safely administered orally or parenterally, per se or in admixture with suitable,
35 pharmaceutically acceptable carriers, excipients or diluents in various pharmaceutical formulations, such as powders,

granules, tablets, capsules and injectable solutions.

While the dosage level varies depending upon the conditions of the diseases to be treated as well as the administration route, in the case of administration to a human adult for



5 the purpose of treatment of ischemic cardiopathies or hypertension, for example, the compounds may be desirably administered orally at a single dose of, normally about 0.1 to 10 mg/kg, preferably about 0.3 to 3 mg/kg, or
10 intravenously at a single dose of about 0.003 to 0.1 mg/kg, preferably about 0.01 to 0.1 mg/kg, about once to 3 times daily according to the conditions.

In the case of administration to a human adult for the purpose of treatment of cerebral circulatory disorders, for example, the compounds may be desirably administered
15 orally at a single dose of, normally about 0.1 to 50 mg/kg, preferably about 0.3 to 30 mg/kg, or intravenously at a single dose of about 0.003 to 10 mg/kg, preferably about 0.01 to 1 mg/kg, about once to 3 times per day according to the conditions.



The starting compounds (II), (IV), (VI) and (VII) can be produced, for example, by the methods as illustrated in the following reaction schema.


(i) Compound (II)

- 5 (a) In the case of X being aryl which may be substituted or carboxyl which may be esterified or amidated:







- (b) In the case of X being lower alkyl which may be substituted:











(c) In the case of X being hydrogen:






(ii) Compound (IV)



(III) Compound (VI)



(v) Compound (VII)



In the above reaction schema, Hal is halogen (e.g., bromine, chlorine, etc.); and other symbols are as defined hereinbefore.

5 In cases in which a compound of the formula (II) wherein X is aryl which may be substituted or carboxyl which may be esterified or amidated is produced, the compound (XII) can be obtained by reacting the compound (VIII) used as a starting compound with the compound (IX) in a suitable organic solvent (e.g., acetone, acetonitrile, 10 benzene, toluene, methylene chloride, N,N-dimethylformamide, etc.), followed by reaction with the compound (XI). The said reaction is normally carried out preferably by allowing a base such as potassium carbonate and sodium hydrogen-carbonate to coexist in the system for the purpose of 15 accelerating the reaction rate, and the reaction temperature normally is preferably in the range of 0°C to +120°C.

A compound of the formula (XIII) wherein m is 1 or 2 can be produced by oxidizing the compound (XII). The said oxidation reaction is carried out, for example, by using 20 an organic peracid (e.g., m-chloroperbenzoic acid, peracetic acid, etc.) or inorganic oxidizing agent (e.g., hydrogen peroxide, periodic acid, etc.). The above reaction is normally conducted in the presence of water or an organic solvent (e.g., methanol, ethanol, dioxane, 25 dichloromethane, etc.) and ordinarily in the temperature range of about -20°C to +100°C. A compound of the formula (XIII) wherein m is 0 can be used in the subsequent reaction without being subjected to the said oxidation reaction.

30 The ring-closure reaction to yield the compound (XIV) from the compound (XIII) is normally carried out in an organic solvent (e.g., N,N-dimethylformamide, acetonitrile, methanol, dimethylsulfoxide, etc.), and is allowed to

proceed advantageously in the presence of a base (e.g., sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium hydride, etc.). The reaction temperature normally is preferably in the range of -20 to +100°C. In cases in which the compound (XIV) is obtained in the form of an alkali metal salt in the above reaction, such a compound is neutralized with, for example, acetic acid, hydrochloric acid, sulfuric acid, etc., and the compound (XIV) can be isolated by conventional methods.

In the case of a compound of the formula (II) wherein X is lower alkyl which may be substituted, the compound (XX) can be obtained by reacting the compound (VIII) with the compound (XI) to give the compound (XV), then, if necessary, converting the compound (XV) into the compound (XVI), subjecting the compound (XVI) to a ring-closure reaction, followed by alkylation, and subjecting the alkylated compound to a reaction of removing the ester group.

The reaction between the compounds (VIII) and (XI) can be carried out in the same manner as the reaction of the compound (VIII) with the compound (IX). The conversion of the compound (XV) into the compound (XVI) can be conducted in the same manner as the conversion of the compound (XII) into the compound (XIII). The ring-closure reaction of (XVI) → (XVII) can be carried out in the same manner as the reaction of (XIII) → (XIV).

The reaction between the compounds (XVII) and (XVIII) can be carried out in an appropriate organic solvent (e.g., acetone, 2-butanone, acetonitrile, N,N-dimethylformamide, dimethylsulfoxide, benzene, toluene, tetrahydrofuran, etc.) in the coexistence of a base (e.g., sodium carbonate, potassium carbonate, sodium hydrogencarbonate, sodium hydride, sodium methoxide, triethylamine, pyridine, etc.). In such a case, the reaction can be allowed to proceed smoothly by adding an iodine compound, such as potassium iodide and sodium iodide, as a catalyst. The reaction

normally is carried out preferably at a temperature in the range of -20°C to $+150^{\circ}\text{C}$.

The reaction of (XIX) \rightarrow (XX) is allowed to proceed by heating the compound (XIX) in an appropriate organic solvent (e.g., dimethylsulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, etc.) in the coexistence of a salt (e.g., sodium chloride, lithium chloride, calcium chloride, sodium bromide, etc.) at a temperature in the range of $+50^{\circ}\text{C}$ to $+160^{\circ}\text{C}$ in accordance with an ordinary reaction of removing the ester group.

In the case of a compound of the formula (II) wherein X is hydrogen, the compound (XXI) can be obtained by subjecting the compound (XVII) to the same reaction as the reaction of (XIX) \rightarrow (XX).

Also, the compound (XVII) can be produced by reacting the compound (VIII) used as a starting compound with the compound (XXII), then oxidizing the sulfur atom to give the compound (XXIV), if desired, subjecting it to the same ring-closure reaction as the above-mentioned reaction and further subjecting the resulting compound (XXV) to an ordinary hydrolysis reaction.

The reaction between the compounds (XIV) and (XXVII) can be carried out in the same manner as the reaction of the compound (XVII) with the compound (XVIII). The compound (XXIX) can be obtained by subjecting the compound (XXVIII) to a reduction reaction. In the said reduction reaction, there may be mentioned reaction conditions of reduction with a metal hydride compound, such as lithium aluminum hydride, lithium borohydride, lithium cyanoborohydride, sodium borohydride, sodium cyanoborohydride, and tri-tert-butoxylithium aluminum hydride; reduction with metallic sodium, metallic magnesium, etc. and alcohols; catalytic reduction using a metal, such as platinum, palladium and rhodium, and a mixture thereof with an arbitrary support as a catalyst; reduction with a metal, such as iron and zinc, and an acid, such as hydrochloric acid and acetic

acid; electrolytic reduction; reduction with a reducing enzyme; reduction with a boron hydride compound, such as diborane, or a complex compound of a boron hydride compound and an amine, such as borane-trimethylamine, and so forth.

5 The above reaction is normally carried out in the presence of water or an organic solvent (e.g., methanol, ethanol, ethyl ether, dioxane, methylene chloride, chloroform, benzene, toluene, acetic acid, dimethylformamide, dimethylacetamide, etc.), and the reaction temperature varies with
10 means of reduction employed, and generally is preferably in the range of -20°C to $+100^{\circ}\text{C}$.

The reaction of (XXIX) \rightarrow (XXX) can be carried out using ordinary means of an acylation or carbamoylation reaction of alcohol derivatives. The said means of an
15 acylation reaction can be realized, for example, by reacting a reactive derivative (e.g., acid anhydride, acid halide, etc.) of an organic acid corresponding to R_5 with the compound (XXIX) in the presence of an organic base (e.g., pyridine, triethylamine, N,N-dimethylaniline, etc.).

20 The above reaction is normally carried out in an organic solvent (e.g., methanol, ethanol, ethyl ether, dioxane, methylene chloride, toluene, dimethylformamide, pyridine, etc.), and the reaction temperature generally is preferably in the range of -20°C to $+100^{\circ}\text{C}$. The carbamoyla-
25 tion reaction can be carried out, for example, by reacting an alcohol derivative (XXIX) as obtained in the reduction reaction with an isocyanate derivative (e.g., methyl isocyanate, ethyl isocyanate, phenyl isocyanate, p-chlorophenyl isocyanate, etc.). The above reaction is
30 normally conducted in an appropriate organic solvent (e.g., methanol, ethanol, acetonitrile, dioxane, tetrahydrofuran, methylene chloride, chloroform, toluene, N,N-dimethylformamide, etc.), and the reaction temperature generally is preferably in the range of -20°C to $+150^{\circ}\text{C}$.

35 The reaction of (XIV) with (XXXI) can be carried out in the same manner as the reaction of (XVII) and (XVIII).

The compound (XXXIII) can be obtained by hydrolyzing the compound (XXXII) with a dilute mineral acid (e.g., hydrochloric acid, sulfuric acid, etc.). The compound (XXXIV) can be obtained by subjecting the compound (XXXII) to the same reduction reaction as the reduction reaction of (XXVIII) \rightarrow (XXIX), and the reaction of (XXXIV) \rightarrow (XXXV) can be carried out in the same manner as the reaction of (XXIX) \rightarrow (XXX). The compound (XXXVI) can be obtained by subjecting the compound (XXXV) to the same reaction as the reaction of (XXXII) \rightarrow (XXXIII).

The reaction between the compounds (XIV) and (XXXVII) can be carried out in the same manner as the reaction of the compound (XVII) with the compound (XVIII). The reaction of (XXXVIII) \rightarrow (XXXIX) can be conducted in the same manner as the reaction of (XXVIII) \rightarrow (XXIX), while the reaction of (XXXIX) \rightarrow (XL) can be carried out in the same manner as the reaction of (XXIX) \rightarrow (XXX).

In the above processes for producing the compound (I) and intermediates thereof, the compounds which are used in the reactions may be used in the form of salts, such as inorganic acid salts being exemplified by hydrochloride, hydrobromide, sulfate, nitrate and phosphate, etc., organic acid salts being exemplified by acetate, tartrate, citrate, fumarate, maleate, toluenesulfonate, methanesulfonate, etc., metal salts being exemplified by sodium salt, potassium salt, calcium salt, aluminum salt, etc., and salts with bases being exemplified by triethylamine salt, guanidine salt, ammonium salt, hydrazine salt, quinine salt, cinchonine salt, etc., so long as they do not interfere with such reactions.

The following Reference Examples, Examples, Experiment Examples and Preparation Examples illustrate the present invention in more detail, but they are by no means limitative of the present invention.

Reference Example 1

In 350 ml of acetone are dissolved 44.7 g of 2-

mercapto-4-methoxyphenol and 88 g of methyl bromoacetate, and 88 g of anhydrous potassium carbonate is added to the solution, followed by stirring at room temperature for 5 hours and then heating under reflux for 5 hours. After the mixture is cooled, the inorganic substance is filtered off, and the filtrate is concentrated under reduced pressure. The residue is recrystallized from ethyl acetate-hexane to give 65 g of colorless crystals of methyl 4-methoxy-2-methoxycarbonylmethylthiophenoxyacetate, melting point of 78°C.

Elemental analysis, for $C_{13}H_{16}O_6S$

Calcd.: C, 51.99; H, 5.37

Found : C, 52.18; H, 5.37

Reference Example 2

In 300 ml of N,N-dimethylformamide is dissolved 94.4 g of methyl 4-methoxy-2-methoxycarbonylmethylthiophenoxyacetate, and 67 g of 28% sodium methoxide is added dropwise to the solution under ice-cooling with stirring. The reaction mixture is stirred for 1 hour and poured into ice-cold water containing dilute hydrochloric acid, and the precipitate is collected by filtration, washed with water, dried and then recrystallized from ethyl acetate-hexane to give 58.7 g of colorless crystals of methyl 7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, m.p. 79-81°C.

Elemental analysis, for $C_{12}H_{12}O_5S$

Calcd.: C, 53.72; H, 4.51

Found : C, 53.72; H, 4.40

Reference Example 3

In 300 ml of acetone are dissolved 28 g of 2-mercapto-4-methoxyphenol and 25 g of chlorodiethylacetamide, and 25 g of anhydrous potassium carbonate is added to the solution, followed by stirring at room temperature under a nitrogen gas stream for 3 hours. Then, 28 g of methyl bromoacetate and 25 g of anhydrous potassium carbonate are added to the reaction mixture, followed by heating under

reflux for 5 hours. After the mixture is cooled, the inorganic substance is filtered off, and the filtrate is concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent: 5 hexane:ethyl acetate=1:1) to give 45 g of a colorless oily material of methyl 2-diethylcarbamoylmethylthio-4-methoxyphenoxyacetate.

Elemental analysis, for $C_{16}H_{23}NO_5S$

Calcd.: C, 56.29; H, 6.79; N, 4.10

10 Found : C, 56.23; H, 6.77; N, 4.18

Reference Example 4

In 160 ml of N,N-dimethylformamide is dissolved 43 g of methyl 2-diethylcarbamoylmethylthio-4-methoxyphenoxy- 15 acetate, and 30 g of 28% sodium methoxide is added dropwise to the solution under ice-cooling and under a nitrogen gas stream with stirring, followed by stirring for 6 hours. The reaction mixture is poured into ice-cold water containing 15 ml of acetic acid, followed by extraction with ethyl acetate. The organic layers are combined, washed with 20 water and dried, and the solvent is evaporated off under reduced pressure. The resulting residue is purified by column chromatography on silica gel (eluent: hexane:ethyl acetate=1:1), followed by recrystallization from ethyl acetate to give colorless prisms of 7-methoxy-3-oxo-3,4- 25 dihydro-2H-1,5-benzoxathiepin-4-diethylcarboxamide, m.p. 112-113°C.

Elemental analysis, for $C_{15}H_{19}NO_4S$

Calcd.: C, 58.23; H, 6.19; N, 4.53

Found : C, 58.17; H, 6.06; N, 4.54

30

Reference Example 5

In 600 ml of acetone are dissolved 60 g of 2-mercapto-4-methoxyphenol and 67 g of chloroacetonitrile, and 125 g of anhydrous potassium carbonate is added to the solution at room temperature under a nitrogen gas stream with stirring, 35 followed by stirring at room temperature for 3 hours and then by heating under reflux for 5 hours. After the

reaction mixture is cooled, the inorganic substance is filtered off, and the filtrate is concentrated under reduced pressure. The residue is recrystallized from ethanol to give colorless prisms of 2-cyanomethylthio-4-methoxyphenoxyacetoneitrile. Yield of 65 g, m.p. of 53-54°C.

Elemental analysis, for $C_{11}H_{10}N_2O_2S$

Calcd.: C, 56.39; H, 4.30; N, 11.96

Found : C, 56.57; H, 4.32; N, 11.78

Reference Example 6

In 120 ml of N,N-dimethylformamide is dissolved 30 g of 2-cyanomethylthio-4-methoxyphenoxyacetoneitrile, and 30 g of 28% sodium methoxide is added dropwise to the solution under ice-cooling and under a nitrogen gas stream with stirring, followed by stirring for 2 hours. The reaction mixture is poured into ice-cold water containing 12 g of acetic acid, and the precipitate is collected by filtration, washed with water and recrystallized from chloroform to give colorless prisms of 3-amino-7-methoxy-2H-1,5-benzoxathiepin-4-carbonitrile. Yield of 19.5 g, m.p. of 203-205°C.

Reference Example 7

In 60 ml of ethanol is suspended 6.0 g of 3-amino-7-methoxy-2H-1,5-benzoxathiepin-4-carbonitrile, and 18 ml of concentrated hydrochloric acid is added to the suspension, followed by stirring at 80 to 90°C for 30 minutes. After the reaction mixture is cooled, ammonium chloride, which separates out, is filtered off, and the filtrate is concentrated under reduced pressure. The residue is recrystallized from ethyl acetate-hexane to give colorless prisms of 7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carbonitrile. Yield of 5.1 g, m.p. of 132-133°C.

Elemental analysis, for $C_{11}H_9NO_3S$

Calcd.: C, 56.16; H, 3.86; N, 5.95

Found : C, 56.08; H, 3.79; N, 5.85

Reference Example 8

In 200 ml of methanol is dissolved 15 g of 7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carbonitrile, and

the solution is saturated with dried hydrogen chloride, followed by allowing the solution to stand at room temperature for 4 days. 10 ml of water is added to the reaction solution, the mixture is allowed to stand overnight and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent; chloroform) to give 6.0 g of methyl 7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in Reference Example 2, together with 6.0 g of the starting material being recovered.

Reference Example 9

A mixture of 2.0 g of methyl 7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, 1.96 g of 1-chloroacetyl 4-phenylpiperazine, 0.6 g of potassium iodide, 1.24 g of anhydrous potassium carbonate and 30 ml of methyl ethyl ketone is heated under reflux for 30 minutes with stirring. The inorganic substance is filtered off, and the filtrate is concentrated under reduced pressure. The resulting residue is dissolved in ethyl acetate, and the solution is washed with water and dried, followed by concentration by evaporation of the solvent under reduced pressure. The residue is purified by column chromatography on silica gel (eluent: hexane:ethyl acetate = 2:1 + 1:1), followed by recrystallization from ethyl acetate-hexane to give 2.1 g of colorless crystals of methyl 7-methoxy-3-oxo-4-[2-oxo-2-(4-phenylpiperazin-1-yl)-ethyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, m.p. of 146-148°C.

IR spectrum (KBr) cm^{-1} : 1740, 1640

NMR spectrum (CDCl_3) δ : 4.78 ppm(2H, double doublet, $\text{C}_4\text{-CH}_2\text{CO-}$)

Elemental analysis, for $\text{C}_{24}\text{H}_{26}\text{N}_2\text{O}_6\text{S}$

Calcd.: C, 61.26; H, 5.57; N, 5.95


Found : C, 61.40; H, 5.60; N, 5.90

Reference Examples 10 to 19

By the same procedure as described in Reference

Example 9, methyl 3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate derivatives are allowed to undergo condensation with halides to give the compounds as shown in Table 1.

Table 1:



Reference Example No.	R ₁	R ₂	X'	Melting point(°C)
10	7-CH ₃ O		$-\text{CH}_2\text{CH}_2\text{CH} \begin{array}{c} \text{O} \\ \diagup \diagdown \\ \text{O} \end{array}$	109-110
11	7-CH ₃ O		$-\text{CH}_2\text{CON}(\text{C}_2\text{H}_5)_2$	Oily material
12	7-CH ₃ O		$-(\text{CH}_2)_3-\text{Br}$	Oily material
13	7-CH ₃ O		$-(\text{CH}_2)_4-\text{Br}$	Oily material
14	7-CH ₃ O		$-(\text{CH}_2)_5-\text{Br}$	Oily material
15	7-CH ₃ O		$-(\text{CH}_2)_6-\text{Br}$	Oily material
16	7-CH ₃ O		$-\text{CH}_2$	Oily material
17	7-CH ₃ O		$-\text{CH}_3$	Oily material
18	7-CH ₃ O		$-\text{CH}_2\text{CO}_2\text{CH}_3$	Oily material
19	7-CH ₃ O		$-(\text{CH}_2)_4-\text{N} \begin{array}{c} \text{O} \\ \diagup \diagdown \\ \text{O} \end{array} \text{ $	78-81

Reference Example 20

In 15 ml of methanol is suspended 1.0 g of methyl 4-diethylcarbamoylmethyl-7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in Reference Example 11, and 0.2 g of sodium borohydride is added portionwise to the suspension under ice-cooling with stirring. When the spot corresponding to the starting compound disappears on the TLC chromatogram, the reaction

mixture is concentrated under reduced pressure, and water is added to the residue, followed by extraction with ethyl acetate. The organic layers are combined, washed with water and dried, and the solvent is evaporated off under reduced pressure. The resulting residue is separated and purified by column chromatography on silica gel (eluent: hexane-ethyl acetate = 1:1), and from the first eluate is obtained 0.117 g of colorless needles of methyl trans-4-diethylcarbamoylmethyl-3-hydroxy-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, m.p. of 120-123°C (recrystallized from ethyl acetate-n-hexane).

Elemental analysis, for $C_{18}H_{25}NO_6S$

Calcd.: C, 56.38; H, 6.57; N, 3.65

Found : C, 56.50; H, 6.73; N, 3.61

From the subsequent eluate, there is obtained 0.587 g of methyl cis-4-diethylcarbamoylmethyl-3-hydroxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate. Recrystallization from ethyl acetate-n-hexane yields colorless prisms, m.p. of 120-122°C.

Elemental analysis, for $C_{18}H_{25}NO_6S$

Calcd.: C, 56.38; H, 6.57; N, 3.65

Found : C, 56.54; H, 6.71; N, 3.65

Reference Example 21

By the same procedure as described in Reference Example 20, the compound as obtained in Reference Example 9 is subjected to a reduction reaction with sodium borohydride to give two kinds of isomers, methyl cis- and trans-3-hydroxy-7-methoxy-4-[2-oxo-2-(4-phenylpiperazin-1-yl)-ethyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate. Cis isomer: Recrystallization from ethyl acetate yields colorless needles, m.p. of 213-215°C. Mass spectrum m/e: 472 (M^+),

Elemental analysis, for $C_{24}H_{28}N_2O_6S$

Calcd.: C, 61.00; H, 5.97; N, 5.93

Found : C, 60.87; H, 5.84; N, 5.86

Hydrochloride of trans isomer: Recrystallization from

methanol-ether yields colorless needles, m.p. of 170-180°C (decomp.)

Elemental analysis, for $C_{24}H_{28}N_2O_6S \cdot HCl \cdot 1/2H_2O$

Calcd.: C, 55.64; H, 5.83; N, 5.40

5 Found : C, 55.38; H, 5.73; N, 5.44

Reference Example 22

10 A 2.0 g quantity of methyl 4-(1,3-dioxolan-2-yl)-ethyl-7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in Reference Example 10, together with 2.0 g of lithium chloride, 0.3 ml of water and 20 ml of dimethylsulfoxide, is stirred at 100°C for 5 hours. After the mixture is cooled, water is added to it, followed by extraction with ethyl acetate. The organic layers are combined, washed with water and dried, and the solvent is
15 evaporated off. The resulting residue is purified by column chromatography on silica gel (eluent: hexane-ethyl acetate = 2:1) to give a colorless oily material of 4-(1,3-dioxolan-2-yl)-ethyl-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-3-one.

20 IR spectrum (neat) cm^{-1} : 1730

NMR spectrum ($CDCl_3$) δ : 1.6-2.3(4H, multiplet), 3.70 ppm (3H, singlet, OCH_3), 3.7-4.2(4H, multiplet), 4.60(2H, doublet), 4.6-5.0(2H, multiplet).

Mass spectrum m/e: 310 (M^+)

25 Reference Example 23

By the same procedure as described in Reference Example 1, methyl 2-methoxycarbonylmethylthiophenoxyacetate is obtained from 2-mercaptophenol and methyl bromoacetate. Recrystallization from hexane-ethyl acetate yields color-
30 less prisms, m.p. of 65-66°C.

Elemental analysis, for $C_{12}H_{14}O_5S$

Calcd.: C, 53.32; H, 5.22

Found : C, 53.20; H, 5.29

Reference Example 24

35 Methyl 2-methoxycarbonylmethylthiophenoxyacetate as obtained in Reference Example 23 is treated in the same

manner as described in Reference Example 2 to give a colorless oily material of methyl 3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

Elemental analysis, for $C_{11}H_{10}O_4S$

5 Calcd.: C, 55.45; H, 4.23

Found : C, 55.33; H, 4.41

Reference Example 25

A mixture of 30 g of methyl 7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, 50 g of 1-bromo-3-chloropropane, 46 g of anhydrous potassium carbonate, 10 g of potassium iodide, 1.0 g of tetrabutyl ammonium iodide and 300 ml of acetonitrile is heated under reflux for 4 hours. After the mixture is cooled, the inorganic substance is filtered off, and the filtrate is concentrated under reduced pressure. The resulting residue is dissolved in ethyl acetate, and the solution is washed with water and dried. The solvent is evaporated off under reduced pressure, and the residue is purified by column chromatography on silica gel (eluent: hexane: ethyl acetate:methylene chloride = 10:1:10). Recrystallization from ethanol yields colorless prisms of methyl 4-(3-chloropropyl)-7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate. Yield of 17 g. m.p. of 64-65°C.

25 Elemental analysis, for $C_{15}H_{17}ClO_5S$

Calcd.: C, 52.25; H, 4.97

Found : C, 52.33; H, 5.10

Reference Example 26

In 200 ml of tetrahydrofuran is dissolved 17 g of methyl 4-(3-chloropropyl)-7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, and 2.8 g of borane-trimethylamine complex and 12 g of boron trifluoride etherate are added to the solution, followed by stirring at room temperature for 20 hours. The reaction solution is concentrated under reduced pressure, and ice-cold water and dilute hydrochloric acid are added to the residue,

followed by extraction with ethyl acetate. The organic layer is washed with water and dried, and the solvent is evaporated off under reduced pressure. The resulting residue is purified by column chromatography on silica gel (eluent: hexane:ethyl acetate = 1:1) to give 13 g of a colorless oily material of methyl cis-4-(3-chloropropyl)-3-hydroxy-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

Elemental analysis, for $C_{15}H_{19}ClO_5S$

Calcd.: C, 51.95; H, 5.52

Found : C, 52.08; H, 5.48

Mass spectrum m/e: 346, 348 (M^+)

Reference Example 27

2-Mercapto-4-methylphenol is treated with methyl bromoacetate in the same manner as described in Reference Example 1 to give methyl 2-methoxycarbonylmethylthio-4-methylphenoxyacetate as colorless prisms (recrystallized from methanol).

mp. 45-46°C.

Elemental Analysis for $C_{13}H_{16}O_5S$

Calcd.: C, 54.92; H, 5.67

10 Found : C, 55.10; H, 5.70

Reference Example 28

4-Chloro-2-mercaptophenol is treated with methyl bromoacetate in the same manner as described in Reference Example 1 to give methyl 4-chloro-2-methoxycarbonylmethylthiophenoxyacetate as colorless prisms (recrystallized from ethyl acetate-hexane).

mp. 76-77°C.

Elemental Analysis for $C_{12}H_{13}ClO_5S$

20 Calcd.: C, 47.30; H, 4.30

Found : C, 47.40; H, 4.29

Reference Example 29

Methyl 2-methoxycarbonylmethylthio-4-methylphenoxyacetate (8.9 g) is treated with sodium methoxide in the same manner as described in Reference Example 2 to give methyl 7-methyl-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate (5.8 g) as a colorless oil.

Mass spectrum (m/e): 252 (M^+).

30 IR $\nu_{\text{max}}^{\text{neat}}$ cm^{-1} : 1730-1750 (C=O)

NMR (CDCl_3) δ : 2.22 (3H, s, $C_7\text{-CH}_3$), 3.80 (3H, s, COOCH_3), 4.62 (2H, double doublet, $C_2\text{-H}$), 4.80 (1H, s, $C_4\text{-H}$).

Reference Example 30

35 Methyl 4-chloro-2-methoxycarbonylmethylthiophenoxyacetate is treated with sodium methoxide in the same

manner as described in Reference Example 2 to give methyl 7-chloro-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as colorless needles, mp. 92-94°C.

Elemental Analysis for $C_{11}H_9ClO_4S$

Calcd.: C, 48.45; H, 3.33

Found : C, 48.45; H, 3.06

Reference Example 31

Methyl 7-methyl-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate (4.1 g) is treated with 1-bromo-3-chloropropane in the same manner as described in Reference Example 25 to give methyl 4-(3-chloropropyl)-7-methyl-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate (2.0 g) as a colorless oil.

Mass spectrum (m/e): 328, 330 (M^+).

IR ν_{\max}^{neat} cm^{-1} : 1760, 1730 (C=O)

NMR (CDCl_3) δ : 2.20 (3H, s, $C_7\text{-CH}_3$), 3.70 (3H, s, CO_2CH_3), 4.62 (2H, double doublet, $C_2\text{-H}$).

Reference Example 32

Methyl 4-(3-chloropropyl)-7-methyl-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate 2.0 g is reduced by sodium borohydride in the same manner as described in Reference Example 20 to give Methyl cis- and trans- 4-(3-chloropropyl)-3-hydroxy-7-methyl-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

cis-isomer (1.2 g, colorless oil)

IR ν_{\max}^{neat} cm^{-1} : 3520 (OH), 1730 (C=O).

NMR (CDCl_3) δ : 2.28ppm (3H, s, $C_7\text{-CH}_3$)

3.78ppm (3H, s, CO_2CH_3)

trans-isomer (0.7 g, colorless oil)

IR ν_{\max}^{neat} cm^{-1} : 3540 (OH), 1720 (C=O)

NMR (CDCl_3) δ : 2.24ppm (3H, s, $C_7\text{-CH}_3$)

3.55ppm (3H, s, CO_2CH_3)

Reference Example 33

Methyl 7-chloro-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate is treated with 1-bromo-3-chloropropane in the same manner as described in Reference Example 25 to give methyl 7-chloro-4-(3-chloropropyl)-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as a colorless oil.

IR $\nu_{\text{max}}^{\text{neat}}$ cm^{-1} : 1760, 1730 (C=O)

NMR (CDCl_3) δ : 3.68ppm (3H, s, CO_2CH_3)

10 4.62ppm (2H, double doublet, $\text{C}_2\text{-H}$).

Reference Example 34

Methyl 7-chloro-4-(3-chloropropyl)-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate is reduced by sodium borohydride in the same manner as described in Reference Example 20 to give methyl cis- and trans- 7-chloro-4-(3-chloropropyl)-3-hydroxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

cis-isomer (colorless oil)

20 IR $\nu_{\text{max}}^{\text{neat}}$ cm^{-1} : 3520 (OH), 1730 (C=O)

NMR (CDCl_3) δ : 3.80ppm (3H, s, CO_2CH_3)

trans-isomer (colorless oil)

IR $\nu_{\text{max}}^{\text{neat}}$ cm^{-1} : 3520 (OH), 1720 (C=O)

NMR (CDCl_3) δ : 3.60ppm (3H, s, CO_2CH_3).

25

Reference Example 35

A mixture of methyl 4-(3-chloropropyl)-7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate (5.0 g) obtained in Reference Example 25, dimethylsulfoxide (30 ml), water (0.3 ml) and lithium chloride (1.5 g) is heated at 100°C for 5 hours with stirring. The reaction mixture is poured into ice-water and extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The residue is submitted to column chromatography on silica gel eluting with hexane-ethyl acetate (2:1) to give

35

4-(3-chloropropyl)-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-3-one (2.0 g) as a colorless oil.

Elemental Analysis for $C_{13}H_{15}ClO_3S$

Calcd.: C, 54.45; H, 5.27

5 Found : C, 54.60; H, 5.24

Mass spectrum (m/e): 286, 288 (M^+).

Reference Example 36

10 To a solution of 4-(3-chloropropyl)-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-3-one (0.8 g) in tetrahydrofuran (2 ml) and methanol (10 ml) is added sodium borohydride (0.1 g) under ice-cooling. The reaction mixture is stirred for one hour and evaporated in vacuo. The residue is mixed with ethyl acetate and water.
15 The organic layer is separated, washed with water, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The residue is submitted to column chromatography on silica gel eluting with ethyl acetate-hexane (1:1) to give 4-(3-chloropropyl)-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-3-ol (0.68 g) as a colorless oil.
20

Elemental Analysis for $C_{13}H_{17}ClO_3S$

Calcd.: C, 54.03; H, 5.93

Found : C, 54.37; H, 6.13

25

Reference Example 37

To a solution of methyl cis-4-(3-chloropropyl)-3-hydroxy-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate (3.5 g) in methanol (50 ml) is added a solution of 1N NaOH (10 ml) and the mixture is stirred for 15 hours. The reaction
30 mixture is evaporated in vacuo. After addition of water (50 ml) to the residue, the mixture is washed with ethyl ether. The aqueous layer is acidified with dil. HCl solution and extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous Na_2SO_4
35 and evaporated to dryness in vacuo. The residue is recrystallized from hexane-AcOEt to give cis- 4-(3-

chloropropyl)-3-hydroxy-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylic acid (2.1 g) as colorless prisms, mp. 175-178°C.

Elemental Analysis for $C_{14}H_{17}O_5SCl$

5 Calcd.: C, 50.53; H, 5.15.

 Found : C, 50.69; H, 5.07.

Reference Example 38

10 To a solution of cis-4-(3-chloropropyl)-3-hydroxy-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylic acid (1.0 g) in pyridine (5 ml) is added acetic anhydride (4 ml), and the mixture is allowed to stand at room temperature for 5 hours. The reaction mixture is poured into water and extracted with ethyl acetate. The organic layer is washed
15 with water, dried over anhydrous Na_2SO_4 and evaporated to dryness in vacuo. The residue is recrystallized from AcOEt-hexane to give cis-3-acetoxy-4-(3-chloropropyl)-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylic acid (0.95 g) as colorless prisms, mp 163-165°C.

20 Elemental Analysis for $C_{16}H_{19}O_6SCl$

 Calcd.: C, 51.27; H, 5.11

 Found : C, 51.44; H, 5.17

Reference Example 39

25 To a mixture of cis-3-acetoxy-4-(3-chloropropyl)-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylic acid (0.8 g), benzylamine (0.27 g) and N,N-dimethylformamide (6 ml) is added diethyl phosphorocyanidate (0.52 g) and then triethylamine (0.45 ml) under ice-
30 cooling with stirring. The reaction mixture is stirred under ice-cooling for 10 minutes and at room temperature for a further 3 hours and then poured into ice-water. The crystalline deposit is collected by filtration, washed with water, and then with ethyl acetate and dried to give
35 cis-3-acetoxy-4-(3-chloropropyl)-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-N-benzylcarboxamide (0.57 g) which

is isolated as colorless plates, mp 224-226°C (from ethyl acetate).

Mass spectrum m/e: 463, 465(M⁺)

Elemental Analysis for C₂₃H₂₆NO₅SCl

5 Calcd.: C, 59.54; H, 5.65; N, 3.02

Found : C, 59.81; H, 5.48; N, 2.82

Example 1

A mixture of 10 g of methyl 7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, 9.8 g of 3-(4-phenylpiperazin-1-yl)propyl chloride, 6.2 g of anhydrous potassium carbonate, 3.0 g of potassium iodide and 150 ml of methyl ethyl ketone is stirred with heating under reflux for 25 hours. After the mixture is cooled, the inorganic substance is filtered off, and the filtrate is concentrated under reduced pressure. The resulting residue is dissolved in ethyl acetate, and the solution is washed with water and dried. The solvent is evaporated off under reduced pressure, and the resulting residue is purified by column chromatography on silica gel (eluent: hexane:ethyl acetate = 3:1) to give methyl 7-methoxy-3-oxo-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate. Recrystallization from methanol gives white crystals. m.p. of 110-112°C. Yield of 2.1 g.


Elemental analysis, for $C_{25}H_{30}N_2O_5S$

Calcd.: C, 63.81; H, 6.43; N, 5.95



Found : C, 63.50; H, 6.37; N, 5.71

Examples 2 to 3

By the same procedure as described in Example 1, the compounds as shown in Table 2 are obtained by the reaction of methyl 7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate with an alkyl halide.

Table 2:

0145494

Example No.	R ₁ , R ₂	X'	Elemental analysis (hydrochloride) (Parenthesized figures are calculated values)		
			C	H	N
5 2	7-CH ₃ O		White powder as 3/4hydrate.		
			60.20 (60.10)	6.30 (6.50)	2.57 (2.70)
10 3	7-CH ₃ O		White powder as 1 1/2 hydrate		
			56.03 (56.25)	6.34 (6.25)	2.84 (2.90)

Example 4

A mixture of 1.7 g of methyl 4-(4-bromobutyl)-7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in Reference Example 13, 1.37 g of N-phenylpiperazine, 0.7 g of potassium iodide, 1.2 g of anhydrous potassium carbonate and 30 ml of acetonitrile is stirred with heating under reflux for 1.5 hours. After the mixture is cooled, the inorganic substance is filtered off, and the filtrate is concentrated under reduced pressure. Water is added to the residue, and the mixture is extracted with ethyl acetate. The organic layers are combined, washed with water and dried, and the solvent is evaporated off under reduced pressure. The residue is purified by column chromatography on silica gel (eluent: hexane-ethyl acetate=2:1) to give 1.0 g of a colorless oily material of methyl 7-methoxy-3-oxo-4-[4-(4-phenylpiperazin-1-yl)butyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate. Hydrochloride, white crystals, m.p. of 155-165°C (decomp).

Elemental analysis, for C₂₆H₃₂N₂O₅S·2HCl·1/2H₂O

Calcd.: C, 55.12; H, 6.22; N, 4.95


Found : C, 55.30; H, 6.19; N, 4.96

Examples 5 to 11

By the same procedure as described in Example 4, the





compounds as shown in Table 3 are obtained by the substitution reaction of the halides obtained in Reference Examples 12 to 15 with amines.

Table 3



Ex. No.	R ₁ , R ₂	X'	Hydrochloride Melting Point, (°C)	Elemental Analysis for hydrochloride (parenthesized figures are calculated values)	Mass spectrum m/e
5	7-CH ₃ O		130-150 (decomp.)	2HCl · ½ H ₂ O 56.00 6.41 4.81 (55.85) (6.42) (4.83)	
6	7-CH ₃ O		powder	2 HCl 57.26 6.70 4.74 (57.42) (6.54) (4.79)	
7	7-CH ₃ O		oil (free base)		560 (M ⁺)

0145494

Ex. No.	R ₁ , R ₂	X'	Hydrochloride Melting point (°C)	Elemental Analysis for hydro- chloride (parenthesized figures are calculated values)	Mass spectrum m/e
8	7-CH ₃ O		oil (free base)		504,506 (M ⁺)
9	7-CH ₃ O		oil (free base)		500(M ⁺)
10	7-CH ₃ O		oil (free base)		471(M ⁺)
11	7-CH ₃ O		oil (free base)		503(M ⁺)

Example 12

In a solvent mixture of 40 ml of tetrahydrofuran and 200 ml of methanol is dissolved 38 g of methyl 7-methoxy-3-oxo-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in Example 1, and 3.7 g of sodium borohydride is added portionwise to the solution under ice-cooling with stirring. After the completion of reaction, the solvent is evaporated off under reduced pressure, and water is added to the residue, followed by extraction with ethyl acetate. The organic layers are combined, washed with water and dried, and the solvent is evaporated off under reduced pressure. The resulting residue is separated and purified by column chromatography on silica gel (eluent: hexane-ethyl acetate-methanol = 20:10:1). From the first eluate there is obtained 12 g of a colorless oily material of methyl trans-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

IR spectrum (neat) cm^{-1} : 3520, 1720

NMR spectrum (CDCl_3) δ : 3.45(3H, singlet, OCH_3), 3.60(3H, singlet, OCH_3)

The compound turns into a white powder as the hydrochloride salt.

Elemental analysis, for $\text{C}_{25}\text{H}_{32}\text{N}_2\text{O}_5\text{S} \cdot 2\text{HCl} \cdot 1/2\text{H}_2\text{O}$

Calcd.: C, 54.15; H, 6.36; N, 5.05

Found : C, 54.27; H, 6.20; N, 4.89

From the subsequent eluate, there is obtained 18 g of a colorless oily material of methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

IR spectrum (neat) cm^{-1} : 3530, 1740

NMR spectrum (CDCl_3) δ : 3.60(3H, singlet, OCH_3), 3.62(3H, singlet, OCH_3)

As the hydrochloride salt, m.p. of 165-175°C (decomp.)

Elemental analysis, for $\text{C}_{25}\text{H}_{32}\text{N}_2\text{O}_5\text{S} \cdot 2\text{HCl} \cdot 1/2\text{H}_2\text{O}$


Calcd.: C, 54.15; H, 6.36; N, 5.05

Found : C, 54.02; H, 6.33; N, 5.00




Examples 13 to 22





By the same procedure as described in Example 12, the compounds as obtained in Examples 2 to 11 are subjected to a
5 reduction reaction with sodium borohydride to give the compounds as shown in Table 4.





Table 4







Configuration shows relationship between
OH (3rd position) and CO_2CH_3 (4th position)

Ex. No.	R_1, R_2	X'	configu- ration	Hydrochloride Melting Point ($^{\circ}\text{C}$)	Elemental Analysis for hydro- chloride (parenthesized figures are calculated values) C H N
13	7-OCH ₃	$\text{-(CH}_2\text{)}_3\text{N}$ 	cis + trans	Powder	$\text{C}_{26}\text{H}_{33}\text{NO}_5\text{S}\cdot\text{HCl}\cdot\frac{1}{2}\text{H}_2\text{O}$ 60.47 6.89 2.64 (60.39) (6.82) (2.71)
14	7-OCH ₃	$\text{-(CH}_2\text{)}_3\text{N}$ 	cis + trans	Powder	$\text{C}_{23}\text{H}_{29}\text{NO}_5\text{S}\cdot\text{HCl}\cdot\frac{3}{4}\text{H}_2\text{O}$ 57.44 6.69 2.71 (57.37) (6.59) (2.91)
15a	7-OCH ₃	$\text{-(CH}_2\text{)}_4\text{N}$ 	cis	Powder	$\text{C}_{26}\text{H}_{34}\text{N}_2\text{O}_5\text{S}\cdot 2\text{HCl}\cdot\frac{1}{4}\text{H}_2\text{O}$ 55.30 6.41 4.94 (55.36) (6.52) (4.97)

Ex. No.	R ₁ , R ₂	X'	configuration	Hydrochloride Melting Point (°C)	Elemental Analysis for hydrochloride (parenthesized figures are calculated values)
					C H N
15b	7-OCH ₃		trans	Carbonate 128-130	C ₂₆ H ₃₄ N ₂ O ₅ S · H ₂ CO ₃ 58.97 6.75 5.28 (59.10) (6.61) (5.11)
16	7-OCH ₃		cis	Powder	C ₂₇ H ₃₆ N ₂ O ₅ S · 2HCl · H ₂ O 54.81 6.81 4.73 (54.49) (6.95) (4.85)
17	7-OCH ₃		cis + trans	165-175 free base (112-114)	C ₂₈ H ₃₈ N ₂ O ₅ S (free base) 65.23 7.54 5.27 (65.34) (7.44) (5.44)
18a	7-OCH ₃		cis	free base (133-135)	C ₃₂ H ₃₈ N ₂ O ₅ S (free base) 68.48 6.73 4.97 (68.30) (6.81) (4.98)

Ex. No.	R ₁ , R ₂	X	configuration	Hydrochloride Melting Point (°C)	Elemental Analysis for hydrochloride (parenthesized figures are calculated values)
18b	7-OCH ₃		trans	free base (173-176)	C ₃₂ H ₃₈ N ₂ O ₅ (free base) 68.34 6.81 4.82 (68.30) (6.81) (4.98)
19a	7-CH ₃ O		cis	140-150	C ₂₅ H ₃₁ N ₂ O ₅ SCl · 3/4 H ₂ O 50.64 6.11 4.61 (50.59) (5.85) (4.72)
19b	7-CH ₃ O		trans	free base (112-113)	C ₂₅ H ₃₁ N ₂ O ₅ SCl (free base) 59.28 6.27 5.34 (59.22) (6.16) (5.52)
20a	7-CH ₃ O		cis	Powder	C ₂₆ H ₃₄ N ₂ O ₆ S · 2HCl · 1 1/2 H ₂ O 51.99 6.55 4.39 (51.83) (6.52) (4.65)

Ex. No.	R1, R2	X'	configuration	Hydrochloride Melting Point (°C)	Elemental Analysis for hydrochloride (parenthesized figures are calculated values)
					$\begin{array}{ccc} \text{C} & \text{H} & \text{N} \\ \hline \text{C}_{26}\text{H}_{34}\text{N}_2\text{O}_6\text{S} \cdot 2\text{HCl} \cdot \text{H}_2\text{O} \\ 52.51 & 6.62 & 4.83 \\ (52.61) & (6.45) & (4.72) \end{array}$
20b	7-CH ₃ O		trans	powder	
					$\begin{array}{ccc} \text{C} & \text{H} & \text{N} \\ \hline \text{C}_{24}\text{H}_{31}\text{N}_3\text{O}_5\text{S} \cdot 2\text{HCl} \cdot \frac{7}{4}\text{H}_2\text{O} \\ 49.97 & 6.66 & 7.06 \\ (49.86) & (6.36) & (7.26) \end{array}$
21a	7-CH ₃ O		cis	powder	
					$\begin{array}{ccc} \text{C} & \text{H} & \text{N} \\ \hline \text{C}_{24}\text{H}_{31}\text{N}_3\text{O}_5\text{S} \cdot 2\text{HCl} \cdot \frac{1}{2}\text{H}_2\text{O} \\ 51.75 & 5.97 & 7.54 \\ (51.89) & (6.20) & (7.56) \end{array}$
21b	7-CH ₃ O		trans	powder	
					$\begin{array}{ccc} \text{C} & \text{H} & \text{N} \\ \hline \text{C}_{26}\text{H}_{35}\text{N}_2\text{O}_7\text{S} \cdot \text{HCl} \cdot \text{H}_2\text{O} \\ 56.01 & 6.82 & 2.30 \\ (55.76) & (6.84) & (2.50) \end{array}$
22	7-CH ₃ O		cis + trans	powder	

Example 23

To a tetrahydrofuran solution of sodium monoacetoxyborohydride prepared by suspending 0.1 g of sodium borohydride in 15 ml of tetrahydrofuran and by adding 0.19 g of acetic acid dropwise to the suspension with stirring is added 0.5 g of methyl cis-3-hydroxy-7-methoxy-4-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in Reference Example 21, followed by heating under reflux for 20 hours. The reaction solution is concentrated under reduced pressure, and water is added to the residue, followed by extraction with ethyl acetate. The organic layer is washed with water and dried, and the solvent is evaporated off under reduced pressure. The residue is purified by silica-gel column chromatography (eluent: hexane-ethyl acetate = 1:1) to give 0.2 g of a colorless oily material of methyl cis-3-hydroxy-7-methoxy-4-[2-(4-phenylpiperazin-1-yl)ethyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, which turns into a white powder as the hydrochloride salt.

Elemental analysis, for $C_{24}H_{30}N_2O_5S \cdot 2HCl \cdot 1/4H_2O$
Calcd.: C, 53.77; H, 6.11; N, 5.23
Found : C, 53.67; H, 6.19; N, 5.35

Example 24

To a mixture of 0.24 g of lithium aluminum hydride and 50 ml of ethyl ether is added 0.7 g of methyl cis-3-hydroxy-7-methoxy-4-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in Reference Example 21, followed by heating under reflux for 2 hours. After the reaction mixture is cooled, 0.25 ml of water, 0.25 ml of a 15% aqueous sodium hydroxide solution and 0.75 ml of water are added to it in the mentioned order, followed by stirring for 30 minutes. The precipitate is filtered off and washed with ethyl acetate, and the filtrate and washings are combined and concentrated under reduced pressure. The residue is recrystallized from ethyl acetate to give 0.5 g of

colorless prisms of cis-4-hydroxymethyl-7-methoxy-4-[2-(4-phenylpiperazin-1-yl)ethyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-ol, m.p. of 153-156°C.

Elemental analysis, for $C_{23}H_{30}N_2O_4S$

5 Calcd.: C, 64.16; H, 7.02; N, 6.51

Found : C, 64.30; H, 7.10; N, 6.48

Example 25

Methyl cis-4-diethylcarbamoylmethyl-3-hydroxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in
10 Reference Example 20 is treated in the same manner as described in Example 24 to give a colorless oily material of cis-4-(2-diethylaminoethyl)-4-hydroxymethyl-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-3-ol.

IR spectrum (neat) cm^{-1} : 3400

15 NMR spectrum ($CDCl_3$) δ : 1.00 ppm(6H, triplet, $2CH_3$), 1.75(2H, m), 2.45(6H, m), 3.58(3H, singlet, OCH_3), 3.60(2H, double doublet, CH_2OH), 3.90(2H, singlet, $-O-CH_2-\overset{|}{C}-OH$).

Example 26

20 In 20 ml of methanol is dissolved 0.8 g of 4-(1,3-dioxolan-1-yl)ethyl-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-3-one as obtained in Reference Example 22, and sodium borohydride is added portionwise to the solution with stirring. At the time when the spot corresponding to the
25 starting compound disappears on the thin-layer chromatogram, a solution of 1 N aqueous sodium hydroxide is added to the reaction solution, followed by extraction with ethyl acetate. The organic layers are combined, washed with water and dried, and the solvent is evaporated off under reduced
30 pressure. 5 ml of dioxane, 2 ml of water and 40 mg of p-toluenesulfonic acid are added to the residue, and the mixture is stirred at room temperature for 8 hours. Water is added to the reaction solution, followed by extraction with ethyl acetate. The organic layers are combined, and
35 the solvent is evaporated off under reduced pressure. 10 ml of acetonitrile and 400 ml of 4-phenylpiperazine are

added to the residue thus obtained, followed by stirring at room temperature for 20 hours. 200 mg of sodium cyanoborohydride and 5 ml of methanol are added to the mixture, followed by stirring for a further 10 hours. Sodium hydroxide (1 N) is added to the reaction solution, followed by extraction with ethyl acetate. The organic layers are combined, washed with water and dried, and the solvent is evaporated off under reduced pressure. The resulting residue is separated and purified by silica-gel column chromatography (eluent: hexane-ethyl acetate-methanol = 10:10:1) to give 200 mg of a colorless oily material of 7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-ol, which turns into a white powder as the hydrochloride salt.

Elemental analysis, for $C_{23}H_{30}N_2O_3S \cdot 2HCl \cdot 1/2H_2O$

Calcd.: C, 55.63; H, 6.70; N, 5.64

Found : C, 55.73; H, 6.61; N, 5.64

Example 27

In 10 ml of pyridine is dissolved 0.7 g of cis-4-(2-diethylaminoethyl)-4-hydroxymethyl-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-3-ol as obtained in Example 25, and 6 ml of acetic anhydride is added to the solution, followed by allowing the mixture to stand at room temperature for 3 hours. The reaction solution is poured into ice-cold water, followed by extraction with ethyl acetate. The organic layer is washed with an aqueous sodium hydrogencarbonate solution and water successively, and dried, and the solvent is evaporated off under reduced pressure to give 0.66 g of a colorless oily material of cis-3-acetoxy-4-acetoxymethyl-7-methoxy-4-(2-diethylaminoethyl)-3,4-dihydro-2H-1,5-benzoxathiepin. The hydrochloride salt, when recrystallized from ethanol-ethyl ether, turns into white crystals., m.p. of 177-179°C.

Elemental analysis, for $C_{21}H_{31}NO_6S \cdot HCl \cdot 1/5H_2O$

Calcd.: C, 54.19; H, 7.01; N, 3.06

Found : C, 54.27; H, 7.05; N, 3.06

Example 28

By the same procedure as described in Example 27, the compound as obtained in Example 12 is acetylated to give methyl
cis-3-acetoxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-
5 3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, which, when
recrystallized from ethyl acetate-n-hexane, turns into color-
less prisms, m.p. of 168-170°C. The structure of this product
can be determined by an X-ray analysis of crystals.

Elemental analysis, for $C_{27}H_{35}N_2O_6S$

10 Calcd.: C, 63.01; H, 6.66; N, 5.44

Found : C, 63.01; H, 6.69; N, 5.40

Example 29

By the same procedure as described in Example 24, the
compound as obtained in Example 12 is reduced with lithium
15 aluminum hydride to give cis-4-hydroxymethyl-7-methoxy-4-
[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-
benzoxathiepin-3-ol. Recrystallization from ethyl acetate
yields colorless needles, m.p. of 163-165°C.

Elemental analysis, for $C_{24}H_{32}N_2O_4S$

20 Calcd.: C, 64.84; H, 7.25; N, 6.30

Found : C, 64.76; H, 7.31; N, 6.39

Example 30

In 5 ml of methanol is dissolved 160 mg of methyl cis-3-
hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-
25 dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in
Example 12, and 3 ml of 1N sodium hydroxide is added to the
solution, followed by stirring at 60°C for 1 hour. The reac-
tion solution is concentrated under reduced pressure, and
5 ml of water is added to the residue. The mixture is ad-
30 justed to pH 3 to 4 with 1N hydrochloric acid and cooled, and
the precipitate is collected by filtration, washed with acetone
and dried to give 0.13 g of white crystals of cis-3-hydroxy-7-
methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-
1,5-benzoxathiepin-4-carboxylic acid, m.p. of 250-260°C (decomp.).

35 Elemental analysis, for $C_{24}H_{30}N_2O_5S \cdot H_2O$

Calcd.: C, 60.48; H, 6.77; N, 5.88

Found: C, 60.27; H, 6.73; N, 5.66

Example 31

In 5 ml of N,N-dimethylformamide is dissolved 0.3 g of methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, and 0.08 g of phenyl isocyanate and 0.1 ml of triethylamine are added to the solution, followed by stirring at room temperature for 3 hours. The reaction solution is poured into water, followed by extraction with ethyl acetate. The organic layer is washed with water, dried and concentrated under reduced pressure, and the residue is chromatographed on a column of silica gel. The fractions which are eluted with a mixture of n-hexane:ethyl acetate = 3:1 to 1:1 are collected and concentrated under reduced pressure to give 0.4 g of a colorless oily material of methyl cis-7-methoxy-3-phenylcarbamoyloxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate. Addition of hydrochloric acid-ethanol solution yields 0.3 g of the hydrochloride salt in the form of a powder.

Elemental analysis, for $C_{32}H_{37}N_3O_6S \cdot 2HCl \cdot 1/2H_2O$

Calcd.: C, 57.05; H, 5.99; N, 6.23

Found : C, 56.78; H, 5.96; N, 6.37

Example 32

By the same procedure as described in Example 1, methyl 3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in Reference Example 24 is allowed to undergo condensation with 3-(4-phenylpiperazin-1-yl)propyl chloride, and methyl 3-oxo-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate is isolated as the hydrochloride salt. Recrystallization from methanol produces white crystals, m.p. of 176-178°C.

Elemental analysis, for $C_{24}H_{28}N_2O_4S \cdot HCl \cdot 1/2H_2O$

Calcd.: C, 59.67; H, 6.26; N, 5.80

Found : C, 59.49; H, 6.33; N, 5.79

Example 33

By the same procedure as described in Example 12, methyl 3-oxo-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate hydrochloride
5 is reduced with sodium borohydride, and separation and purification is effected by silica-gel column chromatography (eluent: hexane-ethyl acetate-methanol = 10:10:1). The trans and cis derivatives are obtained from the first and second eluates, respectively.

10 Methyl cis-3-hydroxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate dihydrochloride. Recrystallization from methanol-ethyl acetate yields colorless plates, m.p. of 196-198°C.

Elemental analysis, for $C_{24}H_{30}N_2O_4S \cdot 2HCl$

15 Calcd.: C, 55.92; H, 6.26; N, 5.43

Found : C, 55.73; H, 6.15; N, 5.51

Methyl trans-3-hydroxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate dihydrochloride.

20 White powder (amorphous powder).

Elemental analysis, for $C_{24}H_{30}N_2O_4S \cdot 2HCl \cdot 1/3H_2O$

Calcd.: C, 55.28; H, 6.31; N, 5.37

Found : C, 55.29; H, 6.49; N, 5.11

Example 34

25 In 3 ml of ethanol is dissolved 0.12 g of cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylic acid as obtained in Example 30, and 50 mg of diethyl sulfate and 100 mg of sodium hydrogencarbonate are added to the solution,
30 followed by heating under reflux for 3 hours. The reaction solution is poured into water, followed by extraction with ethyl acetate. The organic layer is washed with water and dried, and the solvent is evaporated off under reduced pressure. The resulting residue is purified by column
35 chromatography on silica gel (eluent: hexane-ethyl acetate = 1:1) to give 50 mg of a colorless oily material of ethyl

cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate, which turns into a white powder (amorphous powder) as the hydrochloride salt.

5 Elemental analysis, for $C_{26}H_{34}N_2O_5S \cdot 2HCl \cdot 1/4H_2O$


Calcd.: C, 55.36; H, 6.52; N, 4.97

Found : C, 55.30; H, 6.64; N, 4.94

Examples 35 to 36

10 By the same procedure as described in Example 4, the compounds as shown in Table 5 are obtained from the compounds as obtained in Reference Example 12.

Table 5:




Ex. No.	R ₁ , R ₂	X'	Melting point °C	Elemental analysis for hydrochloride (parenthesized figures are calculated values)			Mass spectrum m/e
				C	H	N	
20 35	7-CH ₃ O	(CH ₂) ₃ N N-phenyl	Free base 133-135	C ₂₆ H ₃₂ N ₂ O ₆ S · 1/2H ₂ O 60.95 (61.27)	6.30 (6.53)	5.48 (5.50)	500 (M ⁺)
25 36	7-CH ₃ O	(CH ₂) ₃ N N-CH ₂ -phenyl	Oily material				484 (M ⁺)

Examples 37 to 38

30 By the same procedure as described in Example 12, the compounds of Examples 35 and 36 are reduced to give the compounds as shown in Table 6.

Table 6:



Ex. No.	R ₁ , R ₂	X'	Configu- ration	Hydro- chloride Melting point, °C	Elemental analysis for hydrochloride (parenthesized figures are calculated values)		
					C	H	N
5	37a	7-CH ₃ O-(CH ₂) ₃ -N(CH ₂ CH ₂ CH ₂ -OCH ₃)	cis	Powder	C ₂₆ H ₃₄ N ₂ O ₆ S·2HCl 54.56 6.29 5.05 (54.26) (6.30) (4.87)		
	37b	7-CH ₃ O-(CH ₂) ₃ -N(CH ₂ CH ₂ CH ₂ -OCH ₃)	trans	Powder	C ₂₆ H ₃₄ N ₂ O ₆ S·2HCl·1/2H ₂ O 53.67 6.34 4.68 (53.42) (6.38) (4.79)		
10	38a	7-CH ₃ O-(CH ₂) ₃ -N(CH ₂ CH ₂ CH ₂ -CH ₂ -C ₆ H ₅)	cis	Powder	C ₂₆ H ₃₄ N ₂ O ₅ S·2HCl·H ₂ O 54.07 6.61 4.76 (54.07) (6.63) (4.85)		
	38b	7-CH ₃ O-(CH ₂) ₃ -N(CH ₂ CH ₂ CH ₂ -CH ₂ -C ₆ H ₅)	trans	Powder	C ₂₆ H ₃₄ N ₂ O ₅ S·2HCl·3/4H ₂ O 54.40 6.41 4.84 (54.49) (6.60) (4.89)		

15

20

Example 39

A 14 g quantity of methyl cis-4-(3-chloropropyl)-3-hydroxy-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as obtained in Reference Example 26, together with 9.0 g of 4-phenylpiperazine, 9.0 g of anhydrous potassium carbonate, 0.5 g of potassium iodide and 100 ml of acetonitrile, is heated under reflux for 20 hours. After the mixture is cooled, the inorganic substance is filtered off, and the filtrate is concentrated under reduced pressure. The residue is dissolved in ethyl acetate, and the organic layer is washed with water and dried. After the solvent is evaporated off under reduced pressure, the residue is purified by column chromatography on silica gel (eluent: hexane:ethyl acetate:methanol = 10:10:1), and the resulting oily material is crystallized as the hydrochloride salt to give colorless crystals of methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-

yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate dihydrochloride, which is identical with the compound as obtained in Example 12. Yield of 8 g.

The product is recrystallized from 50% ethanol to give colorless prisms of methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate monohydrochloride.

m.p. 154-155°C (determined on a micro melting point apparatus (Yanagimoto)

132°C (decomp.) (determined by the method described in The Pharmacopoeia of Japan)

Elemental analysis, for $C_{25}H_{32}N_2O_5S \cdot HCl \cdot 2H_2O$

Calcd.: C, 55.09; H, 6.84; N, 5.14

Found : C, 55.46; H, 6.77; N, 5.09


IR $\nu_{\text{max}}^{\text{KBr}}$ cm^{-1} : 3600-3300, 1735, 1720, 1600, 1480, 1250









NMR (d_6 -DMSO) δ : 1.3-1.8 ppm (2H), 2.7-3.8 ppm (12H), 3.68 ppm (3H, singlet), 3.75 ppm (3H, singlet), 3.8-4.3 ppm (3H), 6.7-7.4 ppm (8H).

Examples 40 to 48

By the same procedure as described in Example 39, the compounds as shown in Table 7 are obtained by the substitution reaction of methyl cis-4-(3-chloropropyl)-3-hydroxy-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate with various amines.

Table 7:



Ex. No.	Chemical structure	Hydro- chloride Melting point, °C	Elemental analysis for hydro- chloride (parenthesized figures are calculated values)		
			C	H	N
5	40 	Powder	$C_{26}H_{33}NO_5S \cdot HCl \cdot 1/2H_2O$		
			60.14 (60.39)	6.69 (6.82)	2.67 (2.71)
10	41 	Powder	$C_{26}H_{35}NO_7S \cdot HCl \cdot 1/2H_2O$		
			56.68 (56.67)	6.97 (6.77)	2.51 (2.54)
15	42 	Powder	$C_{27}H_{32}FNO_6S \cdot HCl \cdot 1/2H_2O$		
			57.38 (57.59)	5.80 (5.73)	2.40 (2.49)
20	43 	Powder	$C_{26}H_{34}N_2O_5S \cdot 2HCl$		
			55.95 (55.81)	6.52 (6.48)	4.82 (5.01)
25	44 	140-150	$C_{25}H_{31}N_2O_5SF \cdot 2HCl \cdot 1/2H_2O$		
			52.71 (52.44)	5.82 (5.99)	4.79 (4.89)
30	45 	205-210	$C_{19}H_{27}NO_6S \cdot HCl$		
			52.57 (52.59)	6.72 (6.50)	3.19 (3.23)
35	46 	(Free base) 142-145	$C_{20}H_{30}N_2O_5S \cdot 1/2H_2O$		
			57.45 (57.25)	7.40 (7.45)	6.71 (6.68)
40	47 $-N(C_2H_5)_2$	185-188	$C_{19}H_{29}NO_5S \cdot HCl$		
			54.07 (54.34)	7.23 (7.20)	3.34 (3.34)
45	48 	Powder	$C_{20}H_{29}NO_5S \cdot HCl \cdot 1/2H_2O$		
			54.51 (54.47)	7.22 (7.09)	3.23 (3.18)

Example 49

Methyl 7-methyl-3-oxo-3,4-dihydro-2H-1,5-benzoxa-thiepin-4-carboxylate (1.7 g) is alkylated with 3-(4-phenylpiperazin-1-yl)propylchloride in the same manner as described in Example 1 to give methyl 7-methyl-3-oxo-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate (0.9 g) as a colorless oil.

Mass spectrum (m/e): 454(M⁺)

IR $\nu_{\text{max}}^{\text{neat}}$ cm⁻¹: 1760, 1730 (C=O).

NMR (CDCl₃) δ : 2.22ppm(3H, s, C₇-CH₃), 3.72ppm(3H, s, CO₂CH₃), 4.62ppm(2H, double doublet, C₂-H).

The hydrochloride [white crystals; mp, 140-150°C (decomp.)].

Elemental Analysis for C₂₅H₃₀N₂O₄S·2HCl·1/2H₂O .

Calcd.: C, 55.96; H, 6.20; N, 5.22

Found : C, 56.11; H, 6.19; N, 5.11

Example 50

Methyl 7-chloro-3-oxo-3,4-dihydro-2H-1,5-benzoxa-thiepin-4-carboxylate is alkylated with 3-(4-phenylpiperazin-1-yl)propylchloride in the same manner as described in Example 1 to give methyl 7-chloro-3-oxo-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate which is isolated as the hydrochloride [(white crystals), mp, 197-199°C].

Elemental Analysis for C₂₄H₂₇N₂O₄SCl·2HCl·1/4H₂O

Calcd.: C, 52.18; H, 5.38; N, 5.07

Found : C, 52.11; H, 5.11; N, 4.98

Example 51

Methyl 7-methyl-3-oxo-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate (0.9 g) is reduced by sodium borohydride in the same manner as described in Example 12 to give methyl cis- and trans-3-hydroxy-7-methyl-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

cis-Isomer (colorless oil)

IR $\nu_{\text{max}}^{\text{neat}}$ cm^{-1} : 3540 (OH), 1740 (C=O)

10 NMR (CDCl_3) δ : 2.35ppm (3H, s, $\text{C}_7\text{-CH}_3$)
3.75ppm (3H, s, CO_2CH_3)

The hydrochloride of cis-isomer (white powder).

Elemental Analysis for $\text{C}_{25}\text{H}_{32}\text{N}_2\text{O}_4\text{S} \cdot 1.5\text{HCl}$

Calcd.: C, 58.73; H, 6.60; N, 5.48

15 Found : C, 58.68; H, 6.96; N, 5.31

trans-Isomer (colorless oil)

IR $\nu_{\text{max}}^{\text{neat}}$ cm^{-1} : 3550 (OH), 1730 (C=O)

NMR (CDCl_3) δ : 2.25ppm (3H, s, $\text{C}_7\text{-CH}_3$)
3.52ppm (3H, s, CO_2CH_3)

20 The hydrochloride of trans-isomer (white crystals, mp 145-155°C).

Elemental Analysis for $\text{C}_{25}\text{H}_{32}\text{N}_2\text{O}_4\text{S} \cdot 2\text{HCl} \cdot 1/4\text{H}_2\text{O}$

Calcd.: C, 56.23; H, 6.51; N, 5.25

25 Found : C, 56.39; H, 6.53; N, 5.24

Example 52

Methyl 7-chloro-3-oxo-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate is reduced by sodium borohydride in the same manner as described in Example 12 to give methyl cis- and trans-7-chloro-3-hydroxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

The hydrochloride of cis-isomer (white crystals, mp 205-207°C)

35 Elemental Analysis for $\text{C}_{24}\text{H}_{29}\text{N}_2\text{O}_4\text{SCl} \cdot 2\text{HCl} \cdot 1/2\text{H}_2\text{O}$

Calcd.: C, 51.57; H, 5.77; N, 5.01

Found : C,51.77; H,5.79; N,4.97

The hydrochloride of trans-isomer [white crystals, mp 150-160°C (decomp.)].

Elemental Analysis for $C_{24}H_{29}N_2O_4SCl \cdot 2HCl$

5 Calcd.: C,52.42; H,5.68; N,5.09

Found : C,52.24; H,5.76; N,4.97

Example 53

Methyl cis-4-(3-chloropropyl)-3-hydroxy-7-methyl-
10 3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate 0.3 g is
treated with 4-phenylpiperidine in the same manner as
described in Example 39 to give methyl cis-3-hydroxy-7-
methyl-4-[3-(4-phenylpiperidin-1-yl)propyl]-3,4-dihydro-
2H-1,5-benzoxathiepin-4-carboxylate 0.3 g as a colorless
15 oil.

IR $\nu_{\text{max}}^{\text{neat}}$ cm^{-1} : 3530(OH), 1740(C=O)

NMR (CDCl_3) δ : 2.22ppm(3H,s, $C_7\text{-CH}_3$)
3.72ppm(3H,s, CO_2CH_3)

The hydrochloride (white powder).

20 Elemental Analysis for $C_{26}H_{33}NO_4S \cdot HCl \cdot 1/2H_2O$

Calcd.: C,62.32; H,7.04; N,2.80

Found : C,62.41; H,7.06; N,2.70

Example 54

25 Methyl cis-4-(3-chloropropyl)-3-hydroxy-7-methyl-
3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate is treated
with N-methyl-3,4-dimethoxyphenethylamine in the same
manner as described in Example 39 to give methyl cis-3-
hydroxy-7-methyl-4-[3-[N-methyl-2-(3,4-dimethoxyphenyl)-
30 ethylamino]propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-
carboxylate which is isolated as the hydrochloride
(amorphous powder).

Elemental Analysis for $C_{26}H_{34}NO_6S \cdot HCl \cdot 1/2H_2O$

Calcd.: C,58.36; H,6.97; N,2.62

35 Found : C,58.21; H,7.21; N,2.49

Example 55

A mixture of 4-(3-chloropropyl)-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-3-ol 500 mg, N-phenylpiperazine (500 mg), potassium iodide (50 mg), potassium carbonate (400 mg) and N,N-dimethylformamide (10 ml) is heated at 80°C for 8 hours with stirring. The reaction mixture is poured into water, extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The residue is submitted to column chromatography on silica gel eluting with hexane-ethyl acetate-methanol (10:10:1) to give cis-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-ol (colorless oil) which is isolated as the dihydrochloride (amorphous powder).

Elemental Analysis for $C_{23}H_{30}N_2O_3S \cdot 2HCl \cdot 1/2H_2O$
 Calcd.: C, 55.64; H, 6.70; N, 5.64
 Found : C, 55.95; H, 6.53; N, 5.47
 400 MHz NMR (d_6 -DMSO) δ : 3.206ppm(1H, multiplet, J=8.1, 3.8, and 4.6Hz, C_4 -H), 3.776ppm(1H, double doublet, J=12.2 and 8.5Hz, C_2 -H), 4.017ppm(1H, double doublet, J=12.2 and 3.8Hz, C_2 -H), 4.152ppm(1H, double triplet, J=8.5, 3.8 and 3.8Hz, C_3 -H).

Example 56

To a solution of 7-methoxy-3-oxo-3,4-dihydro-2H-1,5-benzoxathiepin-4-diethylcarboxamide (1.8 g) in ethanol (15 ml) is added sodium borohydride (0.3 g). The reaction mixture is stirred at room temperature for 5 hours, then poured into ice-water and extracted with ethyl acetate. The organic layer is washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The obtained residue is submitted to column chromatography on silica gel eluting with ethyl acetate-hexane (1:1) to give 3-hydroxy-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-diethylcarboxamide (1.48 g) as a colorless oil. (IR ν_{max}^{neat} cm^{-1} : 3400, 1635).

Thus obtained alcohol 300 mg is reduced by sodium monoacetoxymethylborohydride in a manner similar to that described in Example 23 and submitted to column chromatography on silica gel eluting with methylene chloride-methanol (10:1) to give cis-4-diethylaminomethyl-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-3-ol as a colorless oil which is crystallized as the hydrochloride from methanol-ethyl acetate (pale yellow prisms (138 mg), mp 160-162°C).

Elemental Analysis for $C_{15}H_{23}NO_3S \cdot HCl$

Calcd.: C, 53.96; H, 7.25; N, 4.20

Found : C, 54.11; H, 7.44; N, 4.13

400 MHz NMR (d_6 -DMSO) : 3.719ppm(1H, double doublet, J=12.5 and 8.31Hz, C_2 -H), 3.819ppm(1H, double triplet, J=7.8, 3.9 and 3.9Hz, C_4 -H), 4.121ppm(1H, double doublet, J=12.5 and 3.9Hz, C_2 -H), 4.297ppm(1H, double triplet, J=8.3, 3.9 and 3.9Hz, C_3 -H).

Example 57

Methyl cis-7-chloro-4-(3-chloropropyl)-3-hydroxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate 0.15 g is treated with N-methyl-2-(3,4-dimethoxyphenyl)ethylamine in the same manner as described in Example 39 to give 0.06 g of methyl cis-7-chloro-3-hydroxy-4-{3-[N-methyl-2-(3,4-dimethoxyphenyl)ethylamino]propyl}-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate as a colorless oil, which is treated with hydrogen chloride to give the hydrochloride as an amorphous powder.

Elemental Analysis for $C_{25}H_{32}ClNO_6S \cdot HCl \cdot 1/2H_2O$

Calcd.: C, 54.05; H, 6.17; N, 2.52

Found : C, 54.05; H, 6.04; N, 2.57

Example 58

Optical resolution of (\pm) methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate (\pm) Methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-

2H-1,5-benzoxathiepin-4-carboxylate (1.3 g) and S-(+)-1,1'-binaphthyl-2,2'-diyl hydrogenphosphate (1.0 g) are dissolved in methanol (50 ml). The solution is evaporated in vacuo. The residue is dissolved in acetone - methanol and allowed to stand in a refrigerator. The crystalline deposit is filtered off and recrystallized three times from acetone - methanol to yield white crystals ($[\alpha]_D^{25} + 175.5$ (c=1.01, methanol)).

A suspension of the obtained crystals in methylene chloride is treated with 1N sodium hydroxide solution. The organic layer is washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo to give a free base as a colorless oil. The obtained base is dissolved in ethanol, treated with hydrogen chloride and evaporated in vacuo. The residue is triturated with methanol-ethyl ether to give (-) methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate dihydrochloride as an amorphous powder.

$[\alpha]_D - 102.0^\circ$ (c=0.54 in methanol)
Elemental Analysis for $C_{25}H_{32}N_2O_5S \cdot 2HCl \cdot 1/2H_2O$
Calcd.: C, 54.15; H, 6.36; N, 5.05
Found : C, 53.98; H, 6.18; N, 4.83

Example 59

In the same manner as described in Example 58, the salt of (+) methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate and R-(-)-1,1'-binaphthyl-2,2'-diyl hydrogenphosphate is recrystallized three times from acetone-methanol to give white crystals ($[\alpha]_D^{25} - 172^\circ$ (c=1.03, methanol)). The obtained salt is treated with 1N sodium hydroxide, followed by treatment with hydrogen chloride to give (+) methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate dihydrochloride as an amorphous powder.

$[\alpha]_D +110.8^\circ$ ($c=0.48$ in methanol)

Elemental Analysis for $C_{25}H_{32}N_2O_5S \cdot 2HCl \cdot 1/2H_2O$

Calcd.: C, 54.15; H, 6.36; N, 5.05

Found : C, 54.11; H, 5.93; N, 4.80

5

Example 60

A mixture of cis-3-acetoxy-4-(3-chloropropyl)-7-methoxy-3,4-dihydro-2H-1,5-benzoxathiepin-4-N-benzylcarboxamide (0.3 g), N-phenylpiperazine (0.13 g), potassium iodide (0.1 g), potassium carbonate (0.12 g) and N,N-dimethylformamide (4 ml) is stirred at 70°C for 2 hours. The reaction mixture is poured into ice-water (20 ml) and extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous Na_2SO_4 and evaporated to dryness in vacuo. The residue is triturated with AcOEt-hexane to give cis-3-acetoxy-7-methoxy-4-[3-(4-phenylpiperazine-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-N-benzylcarboxamide (97 mg) which is isolated as white crystals, mp 178-180°C (from AcOEt)

20

Mass Spectrum m/e: 589 (M^+)

Elemental Analysis for $C_{33}H_{39}N_3O_5S \cdot 1/4H_2O$

Calcd.: C, 66.70; H, 6.70; N, 7.07

Found : C, 66.75; H, 6.63; N, 6.87

Melting points in Reference Examples and Examples shows the values as measured by a micro melting point apparatus (Yanagimono, Japan) unless otherwise specified.

Experiment Example 1

Serotonin S₂-receptor blocking activity (in vitro)
of the compound of the present invention:

[Experimental method]

5 The experiment was carried out in accordance with
the method of Bevan & Osher (Agents Actions, 2, 257, 1972)
with a few modifications. The heart removed from a
hog immediately after being slaughtered at a slaughterhouse
was preserved under ice-cooling, and the left circumflex
10 coronary artery was dissected within 3 hours. The
coronary artery was cut into a ring preparation of about
3 mm in width, which was suspended in a double-wall organ
bath containing 20 ml of Krebs-Henseleit solution using
a pair of suspending hooks. One of the suspending hooks
15 was fixed to the bottom of the organ bath, while the other
was connected to a strain-gauge transducer, and the con-
striction of the ring preparation of the porcine coronary
artery was isometrically measured and recorded on a
polygraph recorder. The organ bath was maintained at 37°C,
20 and the Krebs-Henseleit solution was saturated with a
mixed gas of 97% O₂ + 3% CO₂, with the Krebs-Henseleit
solution being composed of 118.3 mM NaCl, 4.7 mM KCl, 1.2 mM
KH₂PO₄, 2.58 mM CaCl₂·2H₂O, 1.15 mM MgSO₄·7H₂O, 25 mM
NaHCO₃ and 11.1 mM glucose.

25 In 1 to 2 hours when the blood vessel preparation
showed stable resting tension, the resting tension was
readjusted to be 2 g, and 10⁻⁶M serotonin (final concen-
tration) was added to the organ bath at intervals of
about 1 hour to check the responsiveness of the preparation.
30 When the reaction of the blood vessel to 2 to 3 additions
of serotonin became stable, a concentration of the test
compound was added to the organ bath 10 minutes prior to
subsequent addition of serotonin. The serotonergic
blocking effect of the test compound was calculated from
35 the magnitudes of constriction caused by serotonin before
and after the addition of the test compound.

[Experimental results]

The results of the experiment with regard to the compounds of the present invention are shown in Table 8.

Table 8:

5 Serotonin S₂-receptor blocking effect in porcine coronary artery preparation.

Example number	Concn. (M)	No. of cases	Inhibition of constriction by serotonin, %	
10	1	10 ⁻⁵	3	85.7 ± 9.7
		10 ⁻⁶	3	67.2 ± 8.0
	12-(cis-isomer-hydrochloride)	10 ⁻⁶	3	100
		10 ⁻⁷	4	76.0 ± 5.3
15	28	10 ⁻⁵	3	93.3 ± 6.9
		10 ⁻⁶	3	73.5 ± 10.2
	34	10 ⁻⁵	2	100
		10 ⁻⁶	3	83.3 ± 1.0

20

Experiment Example 2

In the same manner as described in Experiment Example 1, the serotonergic blocking effect of the test compound was measured. The results are shown in Table 9.

Table 9

25	Example number	Concn.(M)	No. of cases	Inhibition of constriction by serotonin (%)
	39	10 ⁻⁷	3	57 ± 7.1
	(monohydrochloride)			
	59	10 ⁻⁷	3	70.7 ± 2.0

Experiment Example 3

Oral serotonergic blocking activity of the compounds of the present invention.

[Experimental method]

5 The experiment was carried out using beagle dogs (male) weighing from 10 to 14 kg. Polyethylene tubes were previously implanted into the femoral artery and vein for measurement of systemic blood pressure and for intravenous administration of a test compound, respectively. The
10 surgical operation for implantation of the polyethylene tubes was performed under sterile conditions under anesthesia with sodium pentobarbital (30 mg/kg intravenously administered). The other ends of the polyethylene tubes were led to the dorsal part subcutaneously and exteriorized.

15 Two to 3 days after the operation, the experiment was carried out. The polyethylene tube kept inserted into the artery was connected to a pressure transducer, and the systemic blood pressure was measured and recorded continuously on a polygraph recorder. When 3 to 30 μ g/kg of serotonin
20 was administered intravenously through the polyethylene tube kept inserted into the femoral vein, a transient hypertensive reaction was observed in a dose-dependent manner, and when 30 μ g/kg of serotonin was, for example, given repeatedly at intervals of about 30 minutes, a
25 reproducible hypertensive reaction was noted. Therefore, 30 μ g/kg of serotonin was used in order to investigate into the effect through oral administration of the compound of the present invention. After it was confirmed that 2 to 3 intravenous administrations of 30 μ g/kg of serotonin at
30 intervals of about 30 minutes gave rise to a stable hypertensive reaction, the compound (I) of the present invention [Example 12 (cis isomer·dihydrochloride)] was administered orally in doses of 0.1, 0.3 and 1.0 mg/kg, and the
35 hypertensive reaction to 30 μ g/kg of serotonin was repeatedly examined, thereafter, until the pre-drug level of the hypertension reaction was attained.

[Experiment results]

The results of the experiment are shown in Table 10. The compound of Example 12 (cis isomer dihydrochloride), when given in doses of not less than 0.1 mg/kg, exhibited dose-dependent and persisting inhibition against the hypertensive reaction to serotonin.

Table 10:

Inhibition of the hypertensive reaction to serotonin (30 µg/kg, i.v.) in unanesthetized beagle dogs.

Dose	No. of cases	Maximum inhibition	The time when the maximum inhibition developed	Duration
mg/kg		%	hr. after administration	hr.
0.1	4	27.8	2	4
0.3	4	40.9	3	6
1.0	3	72.0	3	8

Experiment Example 4

Calcium-antagonistic action

[Experimental method]

The mesenterium was excised from a spontaneously hypertensive rat (14 weeks of age, male), and perfused through the mesenteric artery with the Krebs-Henseleit solution under warming at 37°C. The basal flow rate was kept at about 4 ml/min for the perfusion pressure to be about 40 mmHg. Employed as an indication of calcium antagonism was inhibition of the increase in the perfusion pressure provoked by 10 mg/preparation of KCl injected into the mesenteric artery. The test compound was injected into the artery 30 minutes prior to the injection of KCl.

[Experimental results]

The results are shown in Table 11. In the cases of un-treated, control groups, the increase in the perfusion pressure due to KCl was 73 ± 20 (mean value for 8 cases \pm S.E.M.) mmHg, which was designated as 100% in the table.

The compound of Example 12 (cis), when given in doses of 10^{-7} to 3×10^{-6} M, exhibited dose-dependent and significant inhibition of the KCl-induced increase in the perfusion pressure.

Table 11:

Calcium antagonistic action in isolated, perfused mesenterial preparations of rats.

5	Group	Dose(M)	Change in perfusion pressure upon injection of KCl(%) (No. of cases)
	Control	-	100 (8)
		10^{-7}	$84 \pm 3^*$ (3)
	Example 12(cis)	10^{-6}	$51 \pm 14^*$ (5)
10		3×10^{-6}	$30 \pm 2^*$ (3)

Experiment Example 5

Diuretic action

[Experimental method]

Four groups of 5 spontaneously hypertensive rats (13 week of age, male) each were used in the experiment. The test compound was suspended in isotonic saline with a small amount of gum arabic and administered orally in the volume of 25 ml/kg. Isotonic saline containing gum arabic alone was given to the control group. After the administration, each rat was placed in a metabolism cage for collection of urine for 5 hours. The volume of urine and the amounts of urinary Na^+ and K^+ excreted were measured. The concentrations of Na^+ and K^+ were determined using a flame spectrophotometer (Hitachi type 205 DT).

[Experimental results]

The results are shown in Table 12. The compound of Example 12 (cis isomer-dihydrochloride), when administered orally in a dose of 3 mg/kg, tended to promote the secretion of urine as well as of Na^+ and K^+ , and when given orally in a dose of 10 mg/kg, brought about a significant increase in the urinary volume, and tendency toward increases in Na^+ and K^+ excretion. Thirty mg/kg gave rise to significant increases in the urinary volume and in Na^+ and K^+ excretion.

Table 12:

Diuretic action in spontaneously hypertensive rats.

Group	Dose mg/kg orally	No. of animals	Volume of urine ml/100 g/5 hr	Na^+ $\mu\text{eq}/100 \text{ g}/5 \text{ hr}$	K^+ $\mu\text{eq}/100 \text{ g}/5 \text{ hr}$
Control	-	5	1.02 ± 0.10	128 ± 15	59 ± 8
15	3	5	1.41 ± 0.18	160 ± 19	77 ± 5
Example 12(cis)	10	5	$1.74 \pm 0.15^*$	169 ± 20	81 ± 8
	30	5	$1.97 \pm 0.20^{**}$	$192 \pm 15^*$	$88 \pm 9^*$

Student's t-test

* $P < 0.05$, ** $P < 0.01$

Experiment Example 6

In vivo antithrombotic action in the coronary circulation of anesthetized dogs.

[Experimental method]

Adult mongrel dogs, which underwent thoracotomy under

anesthesia with sodium pentobarbital, were used. Intra-coronary thrombosis was produced in accordance with the method of Folts et al. [Circulation, 54, 365 (1976)]. In brief, an arterial cannula was inserted into the left circumflex coronary artery, and the arterial blood was led from the common carotid artery through an extra-corporeal circuit to perfuse the arterial area. The coronary blood flow was measured with an electromagnetic blood flow probe placed in the extracorporeal circuit. A plastic constrictor was set around the circumflex coronary artery to narrow it by about 70 to 80%. The formation of intra-coronary thrombi was judged by the periodically found decrease and increase in coronary blood flow, because it was demonstrated that platelet thrombi are formed at the narrowed region due to turbulent blood flow, and washed away by an increased pressure gradient. And the frequent formation and removal of the thrombi results in periodical change of the coronary blood flow. Thus, the in vivo antithrombotic activity was assessed in terms of the effect of the test compound on the frequency of the change in the coronary blood flow.

The test compound was administered intravenously.

[Experimental results]

When the constrictor was set around the circumflex coronary artery, the coronary blood flow decreased gradually from the initial rate of 20-30 ml/min to several ml/min, and increased abruptly. The decrease and increase in the coronary blood flow were found to take place periodically, and the frequency was 5 to 15/30 minutes.

The compound of Example 12 (cis isomer·dihydrochloride), when administered intravenously in doses of 1 µg/kg and more, was demonstrated to diminish the frequency of the periodical changes in the coronary blood flow in a dose-dependent manner (Table 13), indicating that the compound of Example 12 (cis isomer·dihydrochloride) inhibited the formation of intra-coronary thrombi caused by blood flow

disturbances in vivo.

Table 13:

Effect on the frequency of periodical changes in the coronary blood flow.

Dose	Before adminis- tration	0 to 30 min. after adminis- tration	30 to 60 min. after adminis- tration
1 µg/kg	8.86 ± 1.94	5.71 ± 1.06	3.8 ± 2.62
3	7.25 ± 1.03	4.75 ± 1.80	0***
10	8.0 ± 1.73	0.33 ± 0.33*	0***

The values denote the frequency of periodical changes in the coronary blood flow over the 30-minute period in terms of mean value ± standard error. *: P<0.05, ***: P<0.001

Experimental Example 7

An action to relieve cerebral vasospasm after experimental subarachnoideal hemorrhage

[Experimental method]

Six beagle dogs weighing 10 to 14 kg were used. For cerebrovascular angiography, a polyethylene cannula was previously implanted chronically into the right vertebral artery under pentobarbital anesthesia (30 mg/kg, intravenous administration). Under pentobarbital anesthesia, cerebrovascular angiography was done twice every 2 seconds immediately after injection of 10 ml of a contrast media, iodamide glutamine injection, through the chronically implanted cannula by use of a roentgenograph (MEDIX-50U). Subarachnoideal hemorrhage was induced by injection of 5 ml of fresh autologous blood taken from a vein of the lower extremity into the cisterna magna with a spinal needle under pentobarbital anesthesia 2 days after implantation of the cannula. Cerebrovascular angiography was done before, and 3, 6 and 13 days after subarachnoideal hemorrhage, and the diameter of the basilar artery was measured on the X-ray photograph.

The animals were divided into 2 groups of 3 head each,

and one group was taken as the control, and the other group was given the compound of Example 39 (monohydrochloride salt). The compound concerned was given at doses of 30 mg/kg orally at the day of subarachnoidal hemorrhage, of 1 mg/kg intravenously immediately after subarachnoidal hemorrhage, and of 30 mg/kg orally consecutively every day until the 13th day after subarachnoidal hemorrhage.

[Experimental results]

The diameter of the basilar artery before subarachnoidal hemorrhage and change in the diameter after subarachnoidal hemorrhage are shown in Table 14. In the control group, the basilar arterial diameter decreased by about 40 and 60% 3 and 6 days after subarachnoidal hemorrhage, respectively, indicating occurrence of cerebral vasospasm. On the other hand, in the group treated with the compound, the decrease in the basilar arterial diameter was slight, and the degree of the decrease was significantly lower as compared with that in the control group.

Table 14:

Group	Arterial diameter before subarachnoidal hemorrhage (mm)	Change in arterial diameter after subarachnoidal hemorrhage (%)		
		3 days after	6 days after	13 days after
Control group	1.47±0.02	-38.3±3.7	-59.3±3.8	-12.7±9.9
Treated group	1.07±0.07*	-2.7±2.7**	-20.7±12.0*	-5±5

*: P<0.05

** : P<0.01 (Student t-test)

Experiment Example 8

An action to improve renal circulation

[Experimental method]

Beagle dogs (normal blood pressure) weighing 9 to 14 kg were used. Laparotomy was done along the abdominal middle line under pentobarbital anesthesia. In order to measure renal blood flow, the left renal artery was dis-

sected free, and an electromagnetic flow probe was set around the artery. A polyethylene tubing was retrogradely inserted and fixed into the abdominal aorta to measure systemic blood pressure. The other ends of the lead wire
5 of the electromagnetic flow probe and of the polyethylene tubing were passed beneath the skin and exteriorized at the back of the neck.

One week or more after the surgical operation, the animals were subjected to the experiment under unanesthetized
10 condition. Renal blood flow was measured by an electromagnetic flowmeter, and systemic blood pressure by a pressure transducer. Heart rate was measured with a pulse-rate tachometer triggered by blood pressure pulse waves.

The test compound [Example 39 (monohydrochloride salt)] was orally administered, and an interval of 3 days
15 or more was allowed to elapse between administrations, when the compound was administered repeatedly in the same individual.

[Experimental results]

20 In this series of experiments, when lactose (10 mg/kg, the number of experiments: 7) was orally administered as a control, no change in systemic blood pressure, heart rate and renal blood flow were noted over 7 hours of observation period. By administration of 3 or 10 mg/kg of the test
25 compound, systemic blood pressure was slightly lowered in a dose-dependent manner, while heart rate was not affected. Renal blood flow, however, was markedly increased by these doses, the maximum increases being by about 23 and 46%, respectively, and the action lasted over 7 hours of
30 observation. The results are shown in Table 15.

Table 15:

Doses (mg/kg, orally)	No. of experimental cases	Maximum changes 2 to 3 hours after administration (%)		
		Systemic blood pressure	Heart rate	Renal blood pressure
3	3	-6.6±4.0	+2.8±3.7	+23.2±9.4
10	3	-11.3±0.9	+3.8±5.9	+46.1±8.0

10

Preparation Example

The compounds (I) of the present invention can be used, for example, as a treatment agent for ischemic cardiopathies, in the following examples of formulation.

15 1. Tablets.

- (1) Methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenyl-piperazin -1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate·hydrochloride 10 g
- (2) Lactose 90 g
- (3) Corn starch 29 g
- (4) Magnesium stearate 1 g

For 1000 tablets, 130 g

The above ingredients (1) and (2) and 17 g of (3) are blended, and granulated together with a paste prepared from 7 g of the ingredient (3). 5 g of the ingredient (3) and the ingredient (4) are added to the resulting granules, and the mixture is compressed by a tabletting machine to prepare 1000 tablets of diameter of 7 mm each containing 10 mg of the ingredient (1).

30 2. Capsules

- (1) Methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenyl-piperazin -1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate·hydrochloride 10 g
- (2) Lactose 135 g
- (3) Finely powdered cellulose 70 g

35

(4) Magnesium stearate 5 g
For 1000 capsules, 220 g

All of the above ingredients are blended and filled into 1000 capsules of Gelatin Capsule No. 3 (X Japanese Pharmacopoeia) to prepare 1000 capsules each containing 10 mg of the ingredient (1).


3. Injectable solution.

(1) Methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin -1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate·tartarate 10 g
(2) Sodium chloride 9 g
(3) Chlorobutanol 5 g

All of the ingredients are dissolved in 1000 ml of distilled water, and charged into 1000 brown ampoules each containing 1 ml of the solution. The air in the ampoules is replaced with nitrogen gas and the ampoules are sealed. The entire preparation steps are conducted under sterile conditions.

CLAIMS

1. A compound of the formula:



wherein R_1 and R_2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy,

R_3 and R_4 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom,

X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated,

Y is $>C=O$ or $>CH-OR_5$ in which R_5 is hydrogen, acyl or optionally substituted carbamoyl,

m is an integer of 0 to 2 and n is an integer of 1 to 6, or a salt thereof.

2. A compound according to Claim 1, wherein R_1 and R_2 are independently hydrogen, halogen, hydroxy, C_{1-4} alkyl or C_{1-4} alkoxy,

R_3 and R_4 are independently hydrogen,

(i) C_{1-4} alkyl which may be substituted by C_{3-8} cycloalkyl, halogen, hydroxy, C_{1-4} alkoxy, C_{1-5} alkanoyloxy, mono- or di- C_{1-4} alkylamino, C_{3-8} cycloalkylamino, C_{1-5} alkanoylamino, benzamido, C_{1-4} alkylthio, carbamoyl, $N-C_{1-4}$ alkylcarbamoyl or N,N -di- C_{1-4} alkylcarbamoyl,

(ii) C_{3-8} cycloalkyl which may be substituted by C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-5} alkanoylamino or hydroxy,

(iii) phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy

amino, nitro or hydroxy, or

(iv) R_3 and R_4 , taken together with the nitrogen atom, form a 5 to 7 membered ring which may be substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (4) diphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (5) triphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (6) C_{1-4} alkanoyl, (7) benzoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) phenyl- C_{1-4} alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (9) phenyl- C_{1-4} alkenoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (10) 5 to 7 membered heterocyclic containing 1 to 3 nitrogen atoms,

X is (1) hydrogen, (2) C_{1-4} alkyl, (3) C_{1-4} alkanoyl, (4) hydroxymethyl, (5) C_{1-5} alkanoyloxymethyl, (6) phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (7) phenyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) C_{1-4} alkoxy carbonyl, (9) phenyl- C_{1-4} alkoxy carbonyl, (10) carbamoyl which may be substituted by 1 to 2 members of C_{1-4} alkyl, phenyl or phenyl- C_{1-4} alkyl or (11) carboxy,

Y is $>C=O$ or $>CH-OR_5$

in which R_5 is (i) hydrogen, (ii) C_{1-6} alkanoyl,

(iii) phenyl- C_{1-6} alkanoyl unsubstituted or substituted by

1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (iv) carbamoyl unsubstituted or substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy,

m is an integer of 0 to 2 and

n is an integer of 1 to 6,

or a pharmaceutically acceptable salt thereof,

3. A compound according to Claim 1, wherein R_1 and R_2 are independently hydrogen, halogen, C_{1-4} alkyl or C_{1-4} alkoxy.

4. A compound according to Claim 1, wherein R_1 and R_2 are independently hydrogen or C_{1-4} alkoxy.

5. A compound according to Claim 1, wherein R_3 and R_4 are independently hydrogen, C_{1-4} alkyl, C_{3-8} cycloalkyl, phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or R_3 and R_4 , taken together with the nitrogen atom, form morpholinyl, piperazinyl or piperidyl which may be substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (4) diphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (5) triphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (6) C_{1-4} alkanoyl, (7) benzoyl unsubstituted or substituted

by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) phenyl- C_{1-4} alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (9) phenyl- C_{1-4} alkenoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (10) 5 to 7 membered heterocyclic containing 1 to 3 nitrogen atoms.

6. A compound according to Claim 1, wherein R_3 and R_4 , taken together with the nitrogen atom, form 4-phenyl-piperazinyl in which the phenyl group is unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy.

7. A compound according to Claim 1, wherein R_3 and R_4 , taken together with the nitrogen atom, form 4-phenyl-piperazinyl.

8. A compound according to Claim 1, wherein X is hydrogen, carboxy, C_{1-4} alkoxy carbonyl, hydroxymethyl or C_{1-5} alkanoyloxymethyl.

9. A compound according to Claim 1, wherein X is C_{1-4} alkoxy carbonyl.

10. A compound according to Claim 1, wherein Y is $>C=O$ or $>CH-OR_5$ in which R_5 is (i) hydrogen, (ii) C_{1-6} alkanoyl or (iii) carbamoyl unsubstituted or substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy.

11. A compound according to Claim 1, wherein Y is hydroxy-methine.

12. A compound according to Claim 1, wherein m is 0.


13. A compound according to Claim 1, wherein n is an integer of 2 to 6.

14. A compound according to Claim 1, wherein n is 3.

15. A compound according to Claim 1, wherein R_1 is hydrogen and R_2 is C_{1-4} alkoxy.

16. A compound according to Claim 1, wherein R_1 is hydrogen and R_2 is C_{1-4} alkoxy which is attached at the 7th position of the benzoxathiepin moiety.

17. A compound of the formula:



wherein R_6 is phenyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy,

$R_{2'}$ is C_{1-4} alkoxy, and

X is C_{1-4} alkoxy-carbonyl

or a pharmaceutically acceptable salt thereof.

18. A compound according to Claim 17, wherein R_6 is phenyl.

19. A compound according to Claim 17, wherein $R_{2'}$ is methoxy.

20. A compound according to Claim 17, wherein X is methoxycarbonyl.

21. The compound according to Claim 1, which is methyl 7-methoxy-3-oxo-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

22. The compound according to Claim 1, which is methyl cis-3-acetoxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

23. The compound according to Claim 1, which is ethyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

24. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperidino)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

25. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

26. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate dihydrochloride.

27. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate monohydrochloride.

28. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate


monohydrochloride dihydrate.

29. The compound according to Claim 1, which is (+)methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

30. A pharmaceutical composition which comprises, as an active ingredient, an effective amount of a compound as claimed in any one of Claims 1 to 29 in association with a pharmaceutically acceptable carrier, excipient or diluent therefor.

31. A compound as claimed in any one of Claims 1 to 29 or a pharmaceutical composition as claimed in Claim 30 for use in therapeutical treatment of a mammal.

32. A process for producing a compound of the formula



wherein R_1 and R_2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy,

R_3 and R_4 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom,

X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated,


Y is $>C=O$ or $>CH-OR_5$ in which R_5 is hydrogen, acyl or optionally substituted carbamoyl,

m is an integer of 0 to 2 and n is an integer of 1

to 6,


or a salt thereof, which comprises

(a) subjecting a compound of the formula:




[wherein each of the symbols is as defined hereinbefore]

and a compound of the formula:




[wherein W is halogen or a group represented by the formula:




(wherein R is lower alkyl, phenyl or p-tolyl); other symbols are as defined hereinbefore] to a condensation reaction, a condensation reaction and thereafter a reduction reaction, or a condensation reaction and thereafter a reduction reaction, followed by an acylation or carbamoylation reaction, or


(b) reacting a compound of the formula:




[wherein W' is halogen or a group represented by the formula:




(wherein R' is lower alkyl, phenyl or p-tolyl); other symbols are as defined hereinbefore] with a compound of the formula:




[wherein R_3 and R_4 are as defined hereinbefore], or
(c) reacting a compound of the formula:



[wherein each of the symbols is as defined hereinbefore]
with a compound of the formula:



[wherein R_3 and R_4 are as defined hereinbefore], or
(d) subjecting a compound of the formula:



[wherein each of the symbols is as defined hereinbefore]
to a reduction reaction, and if desired,
(e) converting the thus obtained compound of the formula
(I) into a salt thereof.

33. A process according to Claim 32, wherein the product is a compound of the formula (I) in which R_1 and R_2 are independently hydrogen, halogen, hydroxy, C_{1-4} alkyl or C_{1-4} alkoxy,

R_3 and R_4 are independently hydrogen,

- (i) C_{1-4} alkyl which may be substituted by C_{3-8} cycloalkyl, halogen, hydroxy, C_{1-4} alkoxy, C_{1-5} alkanoyloxy, mono- or di- C_{1-4} alkylamino C_{3-8} cycloalkylamino, C_{1-5} alkanoylamino, benzamido, C_{1-4} alkylthio, carbamoyl, N- C_{1-4} alkylcarbamoyl or N,N-di- C_{1-4} alkylcarbamoyl,
- (ii) C_{3-8} cycloalkyl which may be substituted by C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-5} alkanoylamino or hydroxy,

(iii) phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, or

(iv) R_3 and R_4 , taken together with the nitrogen atom, form a 5 to 7 membered ring which may be substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (4) diphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (5) triphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (6) C_{1-4} alkanoyl, (7) benzoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) phenyl- C_{1-4} alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (9) phenyl- C_{1-4} alkenoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (10) 5 to 7 membered heterocyclic containing 1 to 3 nitrogen atoms,

X is (1) hydrogen, (2) C_{1-4} alkyl, (3) C_{1-4} alkanoyl, (4) hydroxymethyl, (5) C_{1-5} alkanoyloxymethyl, (6) phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (7) phenyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) C_{1-4} alkoxycarbonyl, (9) phenyl- C_{1-4} alkoxycarbonyl, (10) carbamoyl which may be substituted by 1 to 2 members of C_{1-4} alkyl, phenyl or phenyl- C_{1-4} alkyl or (11) carboxy,

Y is $>C=O$ or $>CH-OR_5$

in which R_5 is (i) hydrogen, (ii) C_{1-6} alkanoyl, (iii) phenyl- C_{1-6} alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (iv) carbamoyl unsubstituted or substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy,

m is an integer of 0 to 2 and

n is an integer of 1 to 6,

or a pharmaceutically acceptable salt thereof.

34. A process according to Claim 32 wherein the product is a compound of the formula (I) in which R_1 and R_2 are independently hydrogen, halogen, C_{1-4} alkyl or C_{1-4} alkoxy.

35. A process according to Claim 32, wherein the product is a compound of the formula (I) in which R_1 and R_2 are independently hydrogen or C_{1-4} alkoxy.

36. A process according to Claim 32, wherein the product is a compound of the formula (I) in which R_3 and R_4 are independently hydrogen, C_{1-4} alkyl, C_{3-8} cycloalkyl, phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or R_3 and R_4 , taken together with the nitrogen atom, form morpholinyl, piperazinyl or piperidyl which may be substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (4) diphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3

members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy, (5) triphenyl-C₁₋₄ alkyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy, (6) C₁₋₄ alkanoyl, (7) benzoyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) phenyl-C₁₋₄ alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy, (9) phenyl-C₁₋₄ alkenoyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy or (10) 5 to 7 membered heterocyclic containing 1 to 3 nitrogen atoms.

37. A process according to Claim 32, wherein the product is a compound of the formula (I) in which R₃ and R₄, taken together with the nitrogen atom, form 4-phenylpiperazinyl in which the phenyl group is unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy.

38. A process according to Claim 32, wherein the product is a compound of the formula (I) in which R₃ and R₄, taken together with the nitrogen atom, form 4-phenylpiperazinyl.

39. A process according to Claim 32, wherein the product is a compound of the formula (I) in which X is hydrogen, carboxy, C₁₋₄ alkoxy-carbonyl, hydroxymethyl or C₁₋₅ alkanoyloxymethyl.

40. A process according to Claim 32, wherein the product is a compound of the formula (I) in which X is C₁₋₄ alkoxy-carbonyl.

41. A process according to Claim 32, wherein the product

is a compound of the formula (I) in which Y is >C=O or >CH-OR_5 in which R_5 is (i) hydrogen, (ii) C_{1-6} alkanoyl or (iii) carbamoyl unsubstituted or substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy.

42. A process according to Claim 32, wherein the product is a compound of the formula (I) in which Y is hydroxymethine.

43. A process according to Claim 32, wherein the product is a compound of the formula (I) in which m is 0.


44. A process according to Claim 32, wherein the product is a compound of the formula (I) in which n is an integer of 2 to 6.

45. A process according to Claim 32, wherein the product is a compound of the formula (I) in which n is 3.

46. A process according to Claim 32, wherein the product is a compound of the formula (I) in which R_1 is hydrogen and R_2 is C_{1-4} alkoxy.

47. A process according to Claim 32, wherein the product is a compound of the formula (I) in which R_1 is hydrogen and R_2 is C_{1-4} alkoxy which is attached at the 7th position of the benzoxathiepin moiety.

48. A process according to Claim 32, wherein the product is a compound of the formula:



wherein R_6 is phenyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy,

R_2 is C_{1-4} alkoxy, and

X is C_{1-4} alkoxy carbonyl

or a pharmaceutically acceptable salt thereof.


49. A process according to Claim 48, wherein R_6 is phenyl.

50. A process according to Claim 48, wherein R_2 is methoxy.

51. A process according to Claim 48, wherein X is methoxycarbonyl.

CLAIMS

1. A compound of the formula:



wherein R_1 and R_2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy,

R_3 and R_4 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom,

X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated,

Y is $>C=O$ or $>CH-OR_5$ in which R_5 is hydrogen, acyl or optionally substituted carbamoyl,

m is an integer of 0 to 2 and n is an integer of 1 to 6, or a salt thereof for use in therapeutical treatment of a mammal.

2. A compound according to Claim 1, wherein R_1 and R_2 are independently hydrogen, halogen, hydroxy, C_{1-4} alkyl or C_{1-4} alkoxy,

R_3 and R_4 are independently hydrogen,

(i) C_{1-4} alkyl which may be substituted by C_{3-8} cycloalkyl, halogen, hydroxy, C_{1-4} alkoxy, C_{1-5} alkanoyloxy, mono- or di- C_{1-4} alkylamino, C_{3-8} cycloalkylamino, C_{1-5} alkanoylamino, benzamido, C_{1-4} alkylthio, carbamoyl, N- C_{1-4} alkylcarbamoyl or N,N-di- C_{1-4} alkylcarbamoyl,

(ii) C_{3-8} cycloalkyl which may be substituted by C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-5} alkanoylamino or hydroxy,

(iii) phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy

amino, nitro or hydroxy, or

(iv) R_3 and R_4 , taken together with the nitrogen atom, form 5 to 7 membered ring which may be substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (4) diphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (5) triphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (6) C_{1-4} alkanoyl, (7) benzoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) phenyl- C_{1-4} alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (9) phenyl- C_{1-4} alkenoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (10) 5 to 7 membered heterocyclic containing 1 to 3 nitrogen atoms,

X is (1) hydrogen, (2) C_{1-4} alkyl, (3) C_{1-4} alkanoyl, (4) hydroxymethyl, (5) C_{1-5} alkanoyloxymethyl, (6) phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (7) phenyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) C_{1-4} alkoxycarbonyl, (9) phenyl- C_{1-4} alkoxycarbonyl, (10) carbamoyl which may be substituted by 1 to 2 members of C_{1-4} alkyl, phenyl or phenyl- C_{1-4} alkyl or (11) carboxy,

Y is $>C=O$ or $>CH-OR_5$

in which R_5 is (i) hydrogen, (ii) C_{1-6} alkanoyl, (iii) phenyl- C_{1-6} alkanoyl unsubstituted or substituted by

1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy, (iv) carbamoyl unsubstituted or substituted by (1) C₁₋₄ alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy or (3) phenyl-C₁₋₄ alkyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy,

m is an integer of 0 to 2 and

n is an integer of 1 to 6,

or a pharmaceutically acceptable salt thereof,

3. A compound according to Claim 1, wherein R₁ and R₂ are independently hydrogen, halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy.

4. A compound according to Claim 1, wherein R₁ and R₂ are independently hydrogen or C₁₋₄ alkoxy.

5. A compound according to Claim 1, wherein R₃ and R₄ are independently hydrogen, C₁₋₄ alkyl, C₃₋₈ cycloalkyl, phenyl-C₁₋₄ alkyl which may be substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy or R₃ and R₄, taken together with the nitrogen atom, form morpholinyl, piperazinyl or piperidyl which may be substituted by (1) C₁₋₄ alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy, (3) phenyl-C₁₋₄ alkyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy, (4) diphenyl-C₁₋₄ alkyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy, (5) triphenyl-C₁₋₄ alkyl unsubstituted or substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy, (6) C₁₋₄ alkanoyl, (7) benzoyl unsubstituted or substituted

by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) phenyl- C_{1-4} alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (9) phenyl- C_{1-4} alkenoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (10) 5 to 7 membered heterocyclic containing 1 to 3 nitrogen atoms.

6. A compound according to Claim 1, wherein R_3 and R_4 , taken together with the nitrogen atom, form 4-phenyl-piperazinyl in which the phenyl group is unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy.


7. A compound according to Claim 1, wherein R_3 and R_4 , taken together with the nitrogen atom, form 4-phenyl-piperazinyl.

8. A compound according to Claim 1, wherein X is hydrogen, carboxy, C_{1-4} alkoxy carbonyl, hydroxymethyl or C_{1-5} alkanoyloxymethyl.

9. A compound according to Claim 1, wherein X is C_{1-4} alkoxy carbonyl.

10. A compound according to Claim 1, wherein Y is >C=O or >CH-OR_5 in which R_5 is (i) hydrogen, (ii) C_{1-6} alkanoyl or (iii) carbamoyl unsubstituted or substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy.

11. A compound according to Claim 1, wherein Y is hydroxymethine.
12. A compound according to Claim 1, wherein m is 0.
13. A compound according to Claim 1, wherein n is an integer of 2 to 6.
14. A compound according to Claim 1, wherein n is 3.
15. A compound according to Claim 1, wherein R_1 is hydrogen and R_2 is C_{1-4} alkoxy.
16. A compound according to Claim 1, wherein R_1 is hydrogen and R_2 is C_{1-4} alkoxy which is attached at the 7th position of the benzoxathiepin moiety.
17. A compound of the formula:



wherein R_6 is phenyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy,

$R_{2'}$ is C_{1-4} alkoxy, and

X is C_{1-4} alkoxycarbonyl

or a pharmaceutically acceptable salt thereof.

18. A compound according to Claim 17, wherein R_6 is phenyl.
19. A compound according to Claim 17, wherein $R_{2'}$ is methoxy.


20. A compound according to Claim 17, wherein X is methoxycarbonyl.
21. The compound according to Claim 1, which is methyl 7-methoxy-3-oxo-4-[3-(4-phenylpiperazin-1-yl)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.
22. The compound according to Claim 1, which is methyl cis-3-acetoxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.
23. The compound according to Claim 1, which is ethyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.
24. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperidino)propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.
25. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.
26. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate dihydrochloride.
27. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate monohydrochloride.
28. The compound according to Claim 1, which is methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate

monohydrochloride dihydrate.

29. The compound according to Claim 1, which is (+)methyl cis-3-hydroxy-7-methoxy-4-[3-(4-phenylpiperazin-1-yl)-propyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate.

30. A pharmaceutical composition which comprises, as an active ingredient, an effective amount of a compound as defined in any one of Claims 1 to 29 in association with a pharmaceutically acceptable carrier, excipient or diluent therefor.

31. A process for producing a novel compound of the formula



wherein R_1 and R_2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy,

R_3 and R_4 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom,

X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated,


Y is >C=O or >CH-OR_5 in which R_5 is hydrogen, acyl or optionally substituted carbamoyl,

m is an integer of 0 to 2 and n is an integer of 1

to 6,


or a salt thereof, which comprises

(a) subjecting a compound of the formula:




[wherein each of the symbols is as defined hereinbefore]

and a compound of the fomrula:




[wherein W is halogen or a group represented by the formula:




(wherein R is lower alkyl, phenyl or p-tolyl); other symbols are as defined hereinbefore] to a condensation reaction, a condensation reaction and thereafter a reduction reaction, or a condensation reaction and thereafter a reduction reaction, followed by an acylation or carbamoylation reaction, or


(b) reacting a compound of the formula:




[wherein W' is halogen or a group represented by the formula:




(wherein R' is lower alkyl, phenyl or p-tolyl); other symbols are as defined hereinbefore] with a compound of the formula:




[wherein R_3 and R_4 are as defined hereinbefore], or
 (c) reacting a compound of the formula:



[wherein each of the symbols is as defined hereinbefore]
 with a compound of the formula:



[wherein R_3 and R_4 are as defined hereinbefore], or
 (d) subjecting a compound of the formula:



[wherein each of the symbols is as defined hereinbefore]
 to a reduction reaction, and if desired,
 (e) converting the thus obtained compound of the formula
 (I) into a salt thereof.

32. A process according to Claim 31, wherein the product is a compound of the formula (I) in which R_1 and R_2 are independently hydrogen, halogen, hydroxy, C_{1-4} alkyl or C_{1-4} alkoxy,

R_3 and R_4 are independently hydrogen,

- (i) C_{1-4} alkyl which may be substituted by C_{3-8} cycloalkyl, halogen, hydroxy, C_{1-4} alkoxy, C_{1-5} alkanoyloxy, mono- or di- C_{1-4} alkylamino, C_{3-8} cycloalkylamino, C_{1-5} alkanoylamino, benzamido, C_{1-4} alkylthio, carbamoyl, $N-C_{1-4}$ alkylcarbamoyl or N,N -di- C_{1-4} alkylcarbamoyl,
- (ii) C_{3-8} cycloalkyl which may be substituted by C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-5} alkanoylamino or hydroxy,

(iii) phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, or

(iv) R_3 and R_4 , taken together with the nitrogen atom, form 5 to 7 membered ring which may be substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (4) diphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (5) triphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (6) C_{1-4} alkanoyl, (7) benzoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) phenyl- C_{1-4} alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (9) phenyl- C_{1-4} alkenoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (10) 5 to 7 membered heterocyclic containing 1 to 3 nitrogen atoms,

X is (1) hydrogen, (2) C_{1-4} alkyl, (3) C_{1-4} alkanoyl, (4) hydroxymethyl, (5) C_{1-5} alkanoyloxymethyl, (6) phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (7) phenyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) C_{1-4} alkoxy carbonyl, (9) phenyl- C_{1-4} alkoxy carbonyl, (10) carbamoyl which may be substituted by 1 to 2 members of C_{1-4} alkyl, phenyl or phenyl- C_{1-4} alkyl or (11) carboxy,

Y is $>C=O$ or $>CH-OR_5$

in which R_5 is (i) hydrogen, (ii) C_{1-6} alkanoyl, (iii) phenyl- C_{1-6} alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (iv) carbamoyl unsubstituted or substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy,

m is an integer of 0 to 2 and

n is an integer of 1 to 6,

or a pharmaceutically acceptable salt thereof.

33. A process according to Claim 31 wherein the product is a compound of the formula (I) in which R_1 and R_2 are independently hydrogen, halogen, C_{1-4} alkyl or C_{1-4} alkoxy.

34. A process according to Claim 31, wherein the product is a compound of the formula (I) in which R_1 and R_2 are independently hydrogen or C_{1-4} alkoxy.

35. A process according to Claim 31, wherein the product is a compound of the formula (I) in which R_3 and R_4 are independently hydrogen, C_{1-4} alkyl, C_{3-8} cycloalkyl, phenyl- C_{1-4} alkyl which may be substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or R_3 and R_4 , taken together with the nitrogen atom, form morpholinyl, piperazinyl or piperidyl which may be substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (4) di-phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3

members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (5) triphenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (6) C_{1-4} alkanoyl, (7) benzoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (8) phenyl- C_{1-4} alkanoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy, (9) phenyl- C_{1-4} alkenoyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (10) 5 to 7 membered heterocyclic containing 1 to 3 nitrogen atoms.

36. A process according to Claim 31, wherein the product is a compound of the formula (I) in which R_3 and R_4 , taken together with the nitrogen atom, form 4-phenylpiperazinyl in which the phenyl group is unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy.

37. A process according to Claim 31, wherein the product is a compound of the formula (I) in which R_3 and R_4 , taken together with the nitrogen atom, form 4-phenylpiperazinyl.

38. A process according to Claim 31, wherein the product is a compound of the formula (I) in which X is hydrogen, carboxy, C_{1-4} alkoxycarbonyl, hydroxymethyl or C_{1-5} alkanoyloxymethyl.

39. A process according to Claim 31, wherein the product is a compound of the formula (I) in which X is C_{1-4} alkoxy-carbonyl.

40. A process according to Claim 31, wherein the product

is a compound of the formula (I) in which Y is >C=O or >CH-OR_5 in which R_5 is (i) hydrogen, (ii) C_{1-6} alkanoyl or (iii) carbamoyl unsubstituted or substituted by (1) C_{1-4} alkyl, (2) phenyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy or (3) phenyl- C_{1-4} alkyl unsubstituted or substituted by 1 to 3 members of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, amino, nitro or hydroxy.

41. A process according to Claim 31, wherein the product is a compound of the formula (I) in which Y is hydroxymethine.

42. A process according to Claim 31, wherein the product is a compound of the formula (I) in which m is 0.


43. A process according to Claim 31, wherein the product is a compound of the formula (I) in which n is an integer of 2 to 6.

44. A process according to Claim 31, wherein the product is a compound of the formula (I) in which n is 3.

45. A process according to Claim 31, wherein the product is a compound of the formula (I) in which R_1 is hydrogen and R_2 is C_{1-4} alkoxy.

46. A process according to Claim 31, wherein the product is a compound of the formula (I) in which R_1 is hydrogen and R_2 is C_{1-4} alkoxy which is attached at the 7th position of the benzoxathiepin moiety.

47. A process according to Claim 31, wherein the product is a compound of the formula:



wherein R is phenyl which may be substituted by 1 to 3 members of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, amino, nitro or hydroxy,

R_{2'} is C₁₋₄ alkoxy, and

X is C₁₋₄ alkoxy carbonyl

or a pharmaceutically acceptable salt thereof.

48. A process according to Claim 47, wherein R₆ is phenyl.

49. A process according to Claim 47, wherein R_{2'} is methoxy.

50. A process according to Claim 47, wherein X is methoxycarbonyl.

①



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 145 494
A3

⑫

EUROPEAN PATENT APPLICATION

⑪ Application number: **84308691.9**

⑫ Date of filing: **13.12.84**

⑤ Int. Cl.⁴: **C 07 D 327/02, C 07 D 411/06,
C 07 D 411/12, A 61 K 31/39,
A 61 K 31/495**

③ Priority: **14.12.83 PC /JP83/004 36**
04.04.84 PC /JP84/001 68
01.11.84 PC /JP84/005 26

④ Date of publication of application: **19.06.85**
Bulletin 85/25

⑧ Designated Contracting States: **AT BE CH DE FR GB IT**
LI LU NL SE

⑧ Date of deferred publication of search
report: **26.03.86 Bulletin 86/13**


⑦ Applicant: **Takeda Chemical Industries, Ltd., 27,
Doshomachi 2-chome Higashi-ku, Osaka-shi**
Osaka, 541 (JP)

⑦ Inventor: **Sugihara, Hirosada, 5-604, 2-Minase 2-chome**
Shimamoto-cho, Mishima-gun, Osaka 618 (JP)
Inventor: **Hirata, Minoru, 26-13, Fushiodai 1-chome,**
Ikeda-shi, Osaka 563 (JP)

⑦ Representative: **Laredo, Jack Joseph et al, Elkington and**
Fife High Holborn House 52/54 High Holborn, London,
WC1V 6SH (GB)

⑤ **1,5-Benzoxathiepin derivatives, their production and use.**

⑤ Novel 1,5-benzoxathiepin derivatives of the formula:



[wherein R_1 and R_2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy; R_3 and R_4 are independently hydrogen, optionally substituted lower alkyl or optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom; X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated; Y is $>C=O$ or $>CH-OR_5$ (wherein R_5 is hydrogen, acyl or optionally substituted carbamoyl); m is an integer of 0 to 2; n is an integer of 1 to 6] and salts thereof exhibit serotonin S_2 receptor blocking activity, calcium antagonism, actions to relieve cerebral vasospasm and to improve renal circulation and diuretic and antithrombotic activities, and are of value as a prophylactic and therapeutic agent for ischemic cardiopathies, thrombosis, hypertension and cerebral circulatory disorders.



European Patent
Office

EUROPEAN SEARCH REPORT

0145494
Application number

EP 84 30 8691

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
	No relevant documents have been disclosed -----		C 07 D 327/02 C 07 D 411/06 C 07 D 411/12 A 61 K 31/39 A 61 K 31/495
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			C 07 D 327/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12-12-1985	Examiner FRANCOIS J.C.L.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO Form 1503 03 82

BAD ORIGINAL